{"abstracts-retrieval-response": {"item": {"ait:process-info": {"ait:status": {"@state": "update", "@type": "core", "@stage": "S300"}, "ait:date-delivered": {"@day": "28", "@timestamp": "2024-10-28T21:35:15.000015-04:00", "@year": "2024", "@month": "10"}, "ait:date-sort": {"@day": "01", "@year": "2016", "@month": "12"}}, "bibrecord": {"head": {"author-group": [{"affiliation": {"country": "Thailand", "@afid": "60000881", "@country": "tha", "city": "Chiang Mai", "organization": [{"$": "Department of Pharmaceutical Care"}, {"$": "Faculty of Pharmacy"}, {"$": "Chiang Mai University"}], "affiliation-id": {"@afid": "60000881", "@dptid": "103084327"}, "@dptid": "103084327"}, "author": [{"ce:given-name": "Baralee", "preferred-name": {"ce:given-name": "Baralee", "ce:initials": "B.", "ce:surname": "Punyawudho", "ce:indexed-name": "Punyawudho B."}, "@seq": "1", "ce:initials": "B.", "@_fa": "true", "@type": "auth", "ce:surname": "Punyawudho", "@auid": "23976628300", "ce:indexed-name": "Punyawudho B."}, {"ce:given-name": "Noppaket", "preferred-name": {"ce:given-name": "Noppaket", "ce:initials": "N.", "ce:surname": "Singkham", "ce:indexed-name": "Singkham N."}, "@seq": "2", "ce:initials": "N.", "@_fa": "true", "@type": "auth", "ce:surname": "Singkham", "@auid": "55524284500", "ce:indexed-name": "Singkham N."}]}, {"affiliation": {"country": "Thailand", "@afid": "60016965", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Thai Red Cross AIDS Research Centre"}, {"$": "HIV-NAT"}], "affiliation-id": [{"@afid": "60016965"}, {"@afid": "60031780"}]}, "author": [{"ce:given-name": "Narukjaporn", "preferred-name": {"ce:given-name": "Narukjaporn", "ce:initials": "N.", "ce:surname": "Thammajaruk", "ce:indexed-name": "Thammajaruk N."}, "@seq": "3", "ce:initials": "N.", "@_fa": "true", "@type": "auth", "ce:surname": "Thammajaruk", "@auid": "36451572800", "ce:indexed-name": "Thammajaruk N."}, {"ce:given-name": "Theera", "preferred-name": {"ce:given-name": "Theera", "ce:initials": "T.", "ce:surname": "Dalodom", "ce:indexed-name": "Dalodom T."}, "@seq": "4", "ce:initials": "T.", "@_fa": "true", "@type": "auth", "ce:surname": "Dalodom", "@auid": "57192085320", "ce:indexed-name": "Dalodom T."}, {"ce:given-name": "Stephen J", "preferred-name": {"ce:given-name": "Stephen J.", "ce:initials": "S.J.", "ce:surname": "Kerr", "ce:indexed-name": "Kerr S.J."}, "@seq": "5", "ce:initials": "S.J.", "@date-locked": "2017-09-09T06:14:50.777", "@_fa": "true", "@type": "auth", "ce:surname": "Kerr", "@auid": "7102711578", "ce:indexed-name": "Kerr S.J."}, {"ce:given-name": "Kiat", "preferred-name": {"ce:given-name": "Kiat", "ce:initials": "K.", "ce:surname": "Ruxrungtham", "ce:indexed-name": "Ruxrungtham K."}, "@seq": "7", "ce:initials": "K.", "@date-locked": "2017-07-19T12:19:16.967", "@_fa": "true", "@type": "auth", "ce:surname": "Ruxrungtham", "@auid": "7004208798", "ce:indexed-name": "Ruxrungtham K."}]}, {"affiliation": {"country": "Australia", "@afid": "60026655", "@country": "aus", "city": "Sydney", "organization": [{"$": "The Kirby Institute"}, {"$": "University of New South Wales"}], "affiliation-id": [{"@afid": "60026655"}, {"@afid": "60028333"}]}, "author": [{"ce:given-name": "Stephen J", "preferred-name": {"ce:given-name": "Stephen J.", "ce:initials": "S.J.", "ce:surname": "Kerr", "ce:indexed-name": "Kerr S.J."}, "@seq": "5", "ce:initials": "S.J.", "@date-locked": "2017-09-09T06:14:50.777", "@_fa": "true", "@type": "auth", "ce:surname": "Kerr", "@auid": "7102711578", "ce:indexed-name": "Kerr S.J."}]}, {"affiliation": {"country": "Netherlands", "@afid": "60002483", "@country": "nld", "city": "Amsterdam", "organization": [{"$": "Department of Global Health"}, {"$": "Academic Medical Center"}, {"$": "University of Amsterdam"}, {"$": "Amsterdam Institute for Global Health and Development"}], "affiliation-id": [{"@afid": "60002483", "@dptid": "103175885"}, {"@afid": "60138854"}, {"@afid": "60001157"}], "@dptid": "103175885"}, "author": [{"ce:given-name": "Stephen J", "preferred-name": {"ce:given-name": "Stephen J.", "ce:initials": "S.J.", "ce:surname": "Kerr", "ce:indexed-name": "Kerr S.J."}, "@seq": "5", "ce:initials": "S.J.", "@date-locked": "2017-09-09T06:14:50.777", "@_fa": "true", "@type": "auth", "ce:surname": "Kerr", "@auid": "7102711578", "ce:indexed-name": "Kerr S.J."}]}, {"affiliation": {"country": "Netherlands", "@afid": "60002573", "@country": "nld", "city": "Nijmegen", "organization": {"$": "Radbound University Medical Center"}, "affiliation-id": {"@afid": "60002573"}}, "author": [{"ce:given-name": "David M", "preferred-name": {"ce:given-name": "David M.", "ce:initials": "D.M.", "ce:surname": "Burger", "ce:indexed-name": "Burger D.M."}, "@seq": "6", "ce:initials": "D.M.", "@_fa": "true", "@type": "auth", "ce:surname": "Burger", "@auid": "55540576000", "ce:indexed-name": "Burger D.M."}]}, {"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Faculty of Medicine"}, {"$": "Chulalongkorn University"}], "affiliation-id": {"@afid": "60028190"}}, "author": [{"ce:given-name": "Kiat", "preferred-name": {"ce:given-name": "Kiat", "ce:initials": "K.", "ce:surname": "Ruxrungtham", "ce:indexed-name": "Ruxrungtham K."}, "@seq": "7", "ce:initials": "K.", "@date-locked": "2017-07-19T12:19:16.967", "@_fa": "true", "@type": "auth", "ce:surname": "Ruxrungtham", "@auid": "7004208798", "ce:indexed-name": "Ruxrungtham K."}]}], "citation-title": "Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients", "abstracts": "\u00a9 2016 Informa UK Limited, trading as Taylor & Francis Group.Introduction: Therapeutic drug monitoring (TDM) may be beneficial when applied to antiretroviral (ARV). Even though TDM can be a valuable strategy in HIV management, its role remains controversial. Areas covered: This review provides a comprehensive update on important issues relating to TDM of ARV drugs in HIV-infected patients. Articles from PubMed with keywords relevant to each topic section were reviewed. Search strategies limited to articles published in English. Expert commentary: There is evidence supporting the use of TDM in HIV treatment. However, some limitations need to be considered. The evidence supporting the use of routine TDM for all patients is limited, as it is not clear that this strategy offers any advantages over TDM for selected indications. Selected groups of patients including patients with physiological changes, patients with drug-drug interactions or toxicity, and the elderly could potentially benefit from TDM, as optimized dosing is challenging in these populations.", "correspondence": {"affiliation": {"country": "Thailand", "@country": "tha", "city": "Chiang Mai", "organization": [{"$": "Department of Pharmaceutical Care"}, {"$": "Faculty of Pharmacy"}, {"$": "Chiang Mai University"}]}, "person": {"ce:given-name": "Baralee", "ce:initials": "B.", "ce:surname": "Punyawudho", "ce:indexed-name": "Punyawudho B."}}, "citation-info": {"author-keywords": {"author-keyword": [{"$": "antiretroviral drugs", "@xml:lang": "eng"}, {"$": "HIV", "@xml:lang": "eng"}, {"$": "Therapeutic drug monitoring", "@xml:lang": "eng"}]}, "citation-type": {"@code": "re"}, "citation-language": {"@language": "English", "@xml:lang": "eng"}, "abstract-language": {"@language": "English", "@xml:lang": "eng"}}, "source": {"sourcetitle-abbrev": "Expert Rev. Clin. Pharmacol.", "@country": "gbr", "translated-sourcetitle": {"$": "Expert Review of Clinical Pharmacology", "@xml:lang": "eng"}, "issn": [{"$": "17512441", "@type": "electronic"}, {"$": "17512433", "@type": "print"}], "volisspag": {"voliss": {"@volume": "9", "@issue": "12"}, "pagerange": {"@first": "1583", "@last": "1595"}}, "@type": "j", "publicationyear": {"@first": "2016"}, "publisher": {"publishername": "Taylor and Francis Ltd", "ce:e-address": {"$": "info@expert-reviews.com", "@type": "email"}}, "sourcetitle": "Expert Review of Clinical Pharmacology", "@srcid": "10300153301", "publicationdate": {"month": "12", "year": "2016", "date-text": {"@xfab-added": "true", "$": "1 December 2016"}, "day": "01"}}, "enhancement": {"classificationgroup": {"classifications": [{"@type": "EMCLASS", "classification": [{"classification-code": "30", "classification-description": "Clinical and Experimental Pharmacology"}, {"classification-code": "37", "classification-description": "Drug Literature Index"}, {"classification-code": "38", "classification-description": "Adverse Reactions Titles"}, {"classification-code": "4", "classification-description": "Microbiology: Bacteriology, Mycology, Parasitology and Virology"}]}, {"@type": "ASJC", "classification": [{"$": "3000"}, {"$": "2736"}]}, {"@type": "SUBJABBR", "classification": [{"$": "PHAR"}, {"$": "MEDI"}]}]}, "chemicalgroup": {"chemicals": [{"@source": "esbd", "chemical": [{"cas-registry-number": "106941-25-7", "chemical-name": "adefovir"}, {"cas-registry-number": "161814-49-9", "chemical-name": "amprenavir"}, {"cas-registry-number": "198904-31-3", "chemical-name": "atazanavir"}, {"cas-registry-number": [{"$": "206361-99-1"}, {"$": "635728-49-3"}], "chemical-name": "darunavir"}, {"cas-registry-number": "154598-52-4", "chemical-name": "efavirenz"}, {"cas-registry-number": [{"$": "137530-41-7"}, {"$": "143491-54-7"}, {"$": "143491-57-0"}], "chemical-name": "emtricitabine"}, {"cas-registry-number": "269055-15-4", "chemical-name": "etravirine"}, {"cas-registry-number": [{"$": "226700-79-4"}, {"$": "226700-80-7"}, {"$": "226700-81-8"}], "chemical-name": "fosamprenavir"}, {"cas-registry-number": [{"$": "150378-17-9"}, {"$": "157810-81-6"}, {"$": "180683-37-8"}], "chemical-name": "indinavir"}, {"cas-registry-number": [{"$": "134678-17-4"}, {"$": "134680-32-3"}], "chemical-name": "lamivudine"}, {"cas-registry-number": "192725-17-0", "chemical-name": "lopinavir"}, {"cas-registry-number": [{"$": "159989-64-7"}, {"$": "159989-65-8"}], "chemical-name": "nelfinavir"}, {"cas-registry-number": "129618-40-2", "chemical-name": "nevirapine"}, {"cas-registry-number": "37205-61-1", "chemical-name": "proteinase inhibitor"}, {"cas-registry-number": [{"$": "518048-05-0"}, {"$": "871038-72-1"}, {"$": "889131-29-7"}], "chemical-name": "raltegravir"}, {"cas-registry-number": [{"$": "500287-72-9"}, {"$": "700361-47-3"}], "chemical-name": "rilpivirine"}, {"cas-registry-number": "155213-67-5", "chemical-name": "ritonavir"}, {"cas-registry-number": [{"$": "127779-20-8"}, {"$": "149845-06-7"}], "chemical-name": "saquinavir"}, {"cas-registry-number": [{"$": "147127-19-3"}, {"$": "147127-20-6"}], "chemical-name": "tenofovir"}, {"cas-registry-number": "174484-41-4", "chemical-name": "tipranavir"}, {"cas-registry-number": "7481-89-2", "chemical-name": "zalcitabine"}, {"cas-registry-number": "30516-87-1", "chemical-name": "zidovudine"}]}, {"@source": "nlm", "chemical": {"chemical-name": "Anti-HIV Agents"}}]}}}, "item-info": {"copyright": {"$": "Copyright 2017 Elsevier B.V., All rights reserved.", "@type": "Elsevier"}, "dbcollection": [{"$": "EMBASE"}, {"$": "MEDL"}, {"$": "REAXYSCAR"}, {"$": "SCOPUS"}, {"$": "Scopusbase"}], "history": {"date-created": {"@day": "01", "@timestamp": "BST 03:33:37", "@year": "2017", "@month": "02"}}, "itemidlist": {"itemid": [{"$": "613413269", "@idtype": "PUI"}, {"$": "658503957", "@idtype": "CAR-ID"}, {"$": "20160863820", "@idtype": "EMBASE"}, {"$": "27626677", "@idtype": "MEDL"}, {"$": "20162399596", "@idtype": "REAXYSCAR"}, {"$": "84996607034", "@idtype": "SCP"}, {"$": "84996607034", "@idtype": "SGR"}, {"$": "614633279", "@idtype": "PUIsecondary"}], "ce:doi": "10.1080/17512433.2016.1235972"}}, "tail": {"bibliography": {"@refcount": "150", "reference": [{"ref-fulltext": "Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853\u2013860.", "@id": "1", "ref-info": {"ref-publicationyear": {"@first": "1998"}, "ref-title": {"ref-titletext": "Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV Outpatient Study Investigators"}, "refd-itemidlist": {"itemid": {"$": "2642709177", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "338", "@issue": "13"}, "pagerange": {"@first": "853", "@last": "860"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "F.J.", "@_fa": "true", "ce:surname": "Palella", "ce:suffix": "Jr.", "ce:indexed-name": "Palella F.J."}, {"@seq": "2", "ce:initials": "K.M.", "@_fa": "true", "ce:surname": "Delaney", "ce:indexed-name": "Delaney K.M."}, {"@seq": "3", "ce:initials": "A.C.", "@_fa": "true", "ce:surname": "Moorman", "ce:indexed-name": "Moorman A.C."}]}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "d\u2019Arminio Monforte A, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. Aids. 1998;12(13):1631\u20131637.", "@id": "2", "ref-info": {"ref-publicationyear": {"@first": "1998"}, "ref-title": {"ref-titletext": "Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection"}, "refd-itemidlist": {"itemid": {"$": "7344233149", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "12", "@issue": "13"}, "pagerange": {"@first": "1631", "@last": "1637"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "d\u2019Arminio Monforte", "ce:indexed-name": "d'Arminio Monforte A."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Testa", "ce:indexed-name": "Testa L."}, {"@seq": "3", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Adorni", "ce:indexed-name": "Adorni F."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients:a prospective cohort study Swiss HIV Cohort Study. Lancet. 1999;353(9156):863\u2013868.", "@id": "3", "ref-info": {"ref-publicationyear": {"@first": "1999"}, "ref-title": {"ref-titletext": "Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study Swiss HIV Cohort Study"}, "refd-itemidlist": {"itemid": {"$": "0033550965", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "353", "@issue": "9156"}, "pagerange": {"@first": "863", "@last": "868"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Ledergerber", "ce:indexed-name": "Ledergerber B."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Egger", "ce:indexed-name": "Egger M."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Opravil", "ce:indexed-name": "Opravil M."}]}, "ref-sourcetitle": "Lancet"}}, {"ref-fulltext": "Ahoua L, Guenther G, Pinoges L, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis. 2009;9:81.", "@id": "4", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda"}, "refd-itemidlist": {"itemid": {"$": "67649848130", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "9"}, "pagerange": {"@first": "81"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Ahoua", "ce:indexed-name": "Ahoua L."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Guenther", "ce:indexed-name": "Guenther G."}, {"@seq": "3", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Pinoges", "ce:indexed-name": "Pinoges L."}]}, "ref-sourcetitle": "BMC Infect Dis"}}, {"ref-fulltext": "De Maat MM, Huitema AD, Mulder JW, et al. Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care. Ther Drug Monit. 2003;25(3):367\u2013373.", "@id": "5", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care"}, "refd-itemidlist": {"itemid": {"$": "0038780487", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "25", "@issue": "3"}, "pagerange": {"@first": "367", "@last": "373"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.M.", "@_fa": "true", "ce:surname": "De Maat", "ce:indexed-name": "De Maat M.M."}, {"@seq": "2", "ce:initials": "A.D.", "@_fa": "true", "ce:surname": "Huitema", "ce:indexed-name": "Huitema A.D."}, {"@seq": "3", "ce:initials": "J.W.", "@_fa": "true", "ce:surname": "Mulder", "ce:indexed-name": "Mulder J.W."}]}, "ref-sourcetitle": "Ther Drug Monit"}}, {"ref-fulltext": "Johnston V, Cohen K, Wiesner L, et al. Viral suppression following switch to second-line antiretroviral therapy:associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis. 2014;209(5):711\u2013720.", "@id": "6", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch"}, "refd-itemidlist": {"itemid": {"$": "84894282743", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "209", "@issue": "5"}, "pagerange": {"@first": "711", "@last": "720"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Johnston", "ce:indexed-name": "Johnston V."}, {"@seq": "2", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Cohen", "ce:indexed-name": "Cohen K."}, {"@seq": "3", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Wiesner", "ce:indexed-name": "Wiesner L."}]}, "ref-sourcetitle": "J Infect Dis"}}, {"ref-fulltext": "Zdanowicz MM., The pharmacology of HIV drug resistance. Am J Pharm Educ. 2006;70(5):100.", "@id": "7", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "The pharmacology of HIV drug resistance"}, "refd-itemidlist": {"itemid": {"$": "33750808446", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "70", "@issue": "5"}, "pagerange": {"@first": "100"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.M.", "@_fa": "true", "ce:surname": "Zdanowicz", "ce:indexed-name": "Zdanowicz M.M."}]}, "ref-sourcetitle": "Am J Pharm Educ"}}, {"ref-fulltext": "Guiard-Schmid JB, Poirier JM, Meynard JL, et al. High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother. 2003;47(3):986\u2013990.", "@id": "8", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "High variability of plasma drug concentrations in dual protease inhibitor regimens"}, "refd-itemidlist": {"itemid": {"$": "0037417018", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "47", "@issue": "3"}, "pagerange": {"@first": "986", "@last": "990"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.B.", "@_fa": "true", "ce:surname": "Guiard-Schmid", "ce:indexed-name": "Guiard-Schmid J.B."}, {"@seq": "2", "ce:initials": "J.M.", "@_fa": "true", "ce:surname": "Poirier", "ce:indexed-name": "Poirier J.M."}, {"@seq": "3", "ce:initials": "J.L.", "@_fa": "true", "ce:surname": "Meynard", "ce:indexed-name": "Meynard J.L."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Gunda DW, Kasang C, Kidenya BR, et al. Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania. PLoS One. 2013;8(9):e75118.", "@id": "9", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania"}, "refd-itemidlist": {"itemid": {"$": "84883751630", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "8", "@issue": "9"}, "pagerange": {"@first": "e75118"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.W.", "@_fa": "true", "ce:surname": "Gunda", "ce:indexed-name": "Gunda D.W."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Kasang", "ce:indexed-name": "Kasang C."}, {"@seq": "3", "ce:initials": "B.R.", "@_fa": "true", "ce:surname": "Kidenya", "ce:indexed-name": "Kidenya B.R."}]}, "ref-sourcetitle": "PLoS One"}}, {"ref-fulltext": "Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1\u201310.", "@id": "10", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Overview of therapeutic drug monitoring"}, "refd-itemidlist": {"itemid": {"$": "64249134394", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "24", "@issue": "1"}, "pagerange": {"@first": "1", "@last": "10"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.S.", "@_fa": "true", "ce:surname": "Kang", "ce:indexed-name": "Kang J.S."}, {"@seq": "2", "ce:initials": "M.H.", "@_fa": "true", "ce:surname": "Lee", "ce:indexed-name": "Lee M.H."}]}, "ref-sourcetitle": "Korean J Intern Med"}}, {"ref-fulltext": "Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring:a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239\u20131276.", "@id": "11", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies"}, "refd-itemidlist": {"itemid": {"$": "45749150011", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "49", "@issue": "7"}, "pagerange": {"@first": "1239", "@last": "1276"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.N.", "@_fa": "true", "ce:surname": "Patsalos", "ce:indexed-name": "Patsalos P.N."}, {"@seq": "2", "ce:initials": "D.J.", "@_fa": "true", "ce:surname": "Berry", "ce:indexed-name": "Berry D.J."}, {"@seq": "3", "ce:initials": "B.F.", "@_fa": "true", "ce:surname": "Bourgeois", "ce:indexed-name": "Bourgeois B.F."}]}, "ref-sourcetitle": "Epilepsia"}}, {"ref-fulltext": "Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother. 1994;28(12):1335\u20131339.", "@id": "12", "ref-info": {"ref-publicationyear": {"@first": "1994"}, "ref-title": {"ref-titletext": "Impact of vancomycin therapeutic drug monitoring on patient care"}, "refd-itemidlist": {"itemid": {"$": "0028558848", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "28", "@issue": "12"}, "pagerange": {"@first": "1335", "@last": "1339"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.E.", "@_fa": "true", "ce:surname": "Welty", "ce:indexed-name": "Welty T.E."}, {"@seq": "2", "ce:initials": "A.K.", "@_fa": "true", "ce:surname": "Copa", "ce:indexed-name": "Copa A.K."}]}, "ref-sourcetitle": "Ann Pharmacother"}}, {"ref-fulltext": "Wong SH. Therapeutic drug monitoring for immunosuppressants. Clin Chim Acta. 2001;313(1\u20132):241\u2013253.", "@id": "13", "ref-info": {"ref-publicationyear": {"@first": "2001"}, "ref-title": {"ref-titletext": "Therapeutic drug monitoring for immunosuppressants"}, "refd-itemidlist": {"itemid": {"$": "0034751045", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "313", "@issue": "1-2"}, "pagerange": {"@first": "241", "@last": "253"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.H.", "@_fa": "true", "ce:surname": "Wong", "ce:indexed-name": "Wong S.H."}]}, "ref-sourcetitle": "Clin Chim Acta"}}, {"ref-fulltext": "Donnerer J, Haas BJ, Kessler HH. Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir. Pharmacology. 2008;82(4):287\u2013292.", "@id": "14", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir"}, "refd-itemidlist": {"itemid": {"$": "53849120594", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "82", "@issue": "4"}, "pagerange": {"@first": "287", "@last": "292"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Donnerer", "ce:indexed-name": "Donnerer J."}, {"@seq": "2", "ce:initials": "B.J.", "@_fa": "true", "ce:surname": "Haas", "ce:indexed-name": "Haas B.J."}, {"@seq": "3", "ce:initials": "H.H.", "@_fa": "true", "ce:surname": "Kessler", "ce:indexed-name": "Kessler H.H."}]}, "ref-sourcetitle": "Pharmacology"}}, {"ref-fulltext": "Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. Aids. 2002;16(4):551\u2013560.", "@id": "15", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "Concentration-controlled compared with conventional antiretroviral therapy for HIV infection"}, "refd-itemidlist": {"itemid": {"$": "0037040358", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "16", "@issue": "4"}, "pagerange": {"@first": "551", "@last": "560"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.V.", "@_fa": "true", "ce:surname": "Fletcher", "ce:indexed-name": "Fletcher C.V."}, {"@seq": "2", "ce:initials": "P.L.", "@_fa": "true", "ce:surname": "Anderson", "ce:indexed-name": "Anderson P.L."}, {"@seq": "3", "ce:initials": "T.N.", "@_fa": "true", "ce:surname": "Kakuda", "ce:indexed-name": "Kakuda T.N."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Langmann P, Zilly M, Weissbrich B, et al. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir. Eur J Med Res. 2000;5(2):59\u201362.", "@id": "16", "ref-info": {"ref-publicationyear": {"@first": "2000"}, "ref-title": {"ref-titletext": "Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir"}, "refd-itemidlist": {"itemid": {"$": "0034723466", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "5", "@issue": "2"}, "pagerange": {"@first": "59", "@last": "62"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Langmann", "ce:indexed-name": "Langmann P."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Zilly", "ce:indexed-name": "Zilly M."}, {"@seq": "3", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Weissbrich", "ce:indexed-name": "Weissbrich B."}]}, "ref-sourcetitle": "Eur J Med Res"}}, {"ref-fulltext": "Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy:pharmacological data from the Viradapt Study. Aids. 2000;14(10):1333\u20131339.", "@id": "17", "ref-info": {"ref-publicationyear": {"@first": "2000"}, "ref-title": {"ref-titletext": "Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study"}, "refd-itemidlist": {"itemid": {"$": "0033942065", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "14", "@issue": "10"}, "pagerange": {"@first": "1333", "@last": "1339"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Durant", "ce:indexed-name": "Durant J."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Clevenbergh", "ce:indexed-name": "Clevenbergh P."}, {"@seq": "3", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Garraffo", "ce:indexed-name": "Garraffo R."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Langmann P, Weissbrich B, Desch S, et al. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. Eur J Med Res. 2002;7(7):309\u2013314.", "@id": "18", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients"}, "refd-itemidlist": {"itemid": {"$": "0037167163", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "7", "@issue": "7"}, "pagerange": {"@first": "309", "@last": "314"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Langmann", "ce:indexed-name": "Langmann P."}, {"@seq": "2", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Weissbrich", "ce:indexed-name": "Weissbrich B."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Desch", "ce:indexed-name": "Desch S."}]}, "ref-sourcetitle": "Eur J Med Res"}}, {"ref-fulltext": "De Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet. 2003;42(6):599\u2013605.", "@id": "19", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population"}, "refd-itemidlist": {"itemid": {"$": "0037715158", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "42", "@issue": "6"}, "pagerange": {"@first": "599", "@last": "605"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.E.", "@_fa": "true", "ce:surname": "De Vries-Sluijs", "ce:indexed-name": "De Vries-Sluijs T.E."}, {"@seq": "2", "ce:initials": "J.P.", "@_fa": "true", "ce:surname": "Dieleman", "ce:indexed-name": "Dieleman J.P."}, {"@seq": "3", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Arts", "ce:indexed-name": "Arts D."}]}, "ref-sourcetitle": "Clin Pharmacokinet"}}, {"ref-fulltext": "Dahri K, Ensom MH. Efavirenz and nevirapine in HIV-1 infection:is there a role for clinical pharmacokinetic monitoring? Clin Pharmacokinet. 2007;46(2):109\u2013132.", "@id": "20", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Efavirenz and nevirapine in HIV-1 infection: is there a role for clinical pharmacokinetic monitoring?"}, "refd-itemidlist": {"itemid": {"$": "33846671337", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "46", "@issue": "2"}, "pagerange": {"@first": "109", "@last": "132"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Dahri", "ce:indexed-name": "Dahri K."}, {"@seq": "2", "ce:initials": "M.H.", "@_fa": "true", "ce:surname": "Ensom", "ce:indexed-name": "Ensom M.H."}]}, "ref-sourcetitle": "Clin Pharmacokinet"}}, {"ref-fulltext": "Bazzoli C, Jullien V, Le Tiec C, et al. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet. 2010;49(1):17\u201345.\u2022\u2022 A comprehensive summary of 31 articles providing results of intracellular concentrations of ARV drugs. This article provided evidence of no relationship between plasma and intracellular concentrations of NRTIs.", "@id": "21", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action"}, "refd-itemidlist": {"itemid": {"$": "72249123176", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "49", "@issue": "1"}, "pagerange": {"@first": "17", "@last": "45"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Bazzoli", "ce:indexed-name": "Bazzoli C."}, {"@seq": "2", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Jullien", "ce:indexed-name": "Jullien V."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Le Tiec", "ce:indexed-name": "Le Tiec C."}]}, "ref-sourcetitle": "Clin Pharmacokinet"}}, {"ref-fulltext": "Molto J, Blanco A, Miranda C, et al. Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol. 2006;62(5):560\u2013566.", "@id": "22", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice"}, "refd-itemidlist": {"itemid": {"$": "33749987244", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "62", "@issue": "5"}, "pagerange": {"@first": "560", "@last": "566"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Molto", "ce:indexed-name": "Molto J."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Blanco", "ce:indexed-name": "Blanco A."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Miranda", "ce:indexed-name": "Miranda C."}]}, "ref-sourcetitle": "Br J Clin Pharmacol"}}, {"ref-fulltext": "Cattaneo D, Baldelli S, Castoldi S, et al. Is it time to revise antiretrovirals dosing? A pharmacokinetic viewpoint. Aids. 2014;28(16):2477\u20132480.", "@id": "23", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Is it time to revise antiretrovirals dosing? A pharmacokinetic viewpoint"}, "refd-itemidlist": {"itemid": {"$": "84916208892", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "28", "@issue": "16"}, "pagerange": {"@first": "2477", "@last": "2480"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Cattaneo", "ce:indexed-name": "Cattaneo D."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Baldelli", "ce:indexed-name": "Baldelli S."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Castoldi", "ce:indexed-name": "Castoldi S."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Rezk NL, Tidwell RR, Kashuba AD. High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;805(2):241\u2013247.", "@id": "24", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma"}, "refd-itemidlist": {"itemid": {"$": "2342592624", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "805", "@issue": "2"}, "pagerange": {"@first": "241", "@last": "247"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "N.L.", "@_fa": "true", "ce:surname": "Rezk", "ce:indexed-name": "Rezk N.L."}, {"@seq": "2", "ce:initials": "R.R.", "@_fa": "true", "ce:surname": "Tidwell", "ce:indexed-name": "Tidwell R.R."}, {"@seq": "3", "ce:initials": "A.D.", "@_fa": "true", "ce:surname": "Kashuba", "ce:indexed-name": "Kashuba A.D."}]}, "ref-sourcetitle": "J Chromatogr B Analyt Technol Biomed Life Sci"}}, {"ref-fulltext": "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2016. [cited 2016 Jan]. Available from:https://aidsinfo.nih.gov/\u2022\u2022 Updated guideline for the use of ARV drugs in HIV-1-infected adults and adolescents. The role of TDM in the management of HIV infection was provided.", "@id": "25", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-website": {"ce:e-address": {"$": "https://aidsinfo.nih.gov/", "@type": "email"}}, "refd-itemidlist": {"itemid": {"$": "84879125043", "@idtype": "SGR"}}, "ref-text": "Available from, Jan", "ref-sourcetitle": "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents"}}, {"ref-fulltext": "Van Luin M, Kuks PF, Burger DM. Use of therapeutic drug monitoring in HIV disease. Curr Opin HIV AIDS. 2008;3(3):266\u2013271.", "@id": "26", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Use of therapeutic drug monitoring in HIV disease"}, "refd-itemidlist": {"itemid": {"$": "42049111861", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "3", "@issue": "3"}, "pagerange": {"@first": "266", "@last": "271"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Van Luin", "ce:indexed-name": "Van Luin M."}, {"@seq": "2", "ce:initials": "P.F.", "@_fa": "true", "ce:surname": "Kuks", "ce:indexed-name": "Kuks P.F."}, {"@seq": "3", "ce:initials": "D.M.", "@_fa": "true", "ce:surname": "Burger", "ce:indexed-name": "Burger D.M."}]}, "ref-sourcetitle": "Curr Opin HIV AIDS"}}, {"ref-fulltext": "Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. Aids. 2003;17(8):1157\u20131165.", "@id": "27", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals"}, "refd-itemidlist": {"itemid": {"$": "0037867653", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "17", "@issue": "8"}, "pagerange": {"@first": "1157", "@last": "1165"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Burger", "ce:indexed-name": "Burger D."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Hugen", "ce:indexed-name": "Hugen P."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Reiss", "ce:indexed-name": "Reiss P."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Best BM, Goicoechea M, Witt MD, et al. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007;46(4):433\u2013442.", "@id": "28", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients"}, "refd-itemidlist": {"itemid": {"$": "36048986325", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "46", "@issue": "4"}, "pagerange": {"@first": "433", "@last": "442"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.M.", "@_fa": "true", "ce:surname": "Best", "ce:indexed-name": "Best B.M."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Goicoechea", "ce:indexed-name": "Goicoechea M."}, {"@seq": "3", "ce:initials": "M.D.", "@_fa": "true", "ce:surname": "Witt", "ce:indexed-name": "Witt M.D."}]}, "ref-sourcetitle": "J Acquir Immune Defic Syndr"}}, {"ref-fulltext": "Albrecht M, Mukherjee AL, Tierney C, et al. A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals:week 48 results of the A5146 study. HIV Clin Trials. 2011;12(4):201\u2013214.", "@id": "29", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study"}, "refd-itemidlist": {"itemid": {"$": "80455127179", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "12", "@issue": "4"}, "pagerange": {"@first": "201", "@last": "214"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Albrecht", "ce:indexed-name": "Albrecht M."}, {"@seq": "2", "ce:initials": "A.L.", "@_fa": "true", "ce:surname": "Mukherjee", "ce:indexed-name": "Mukherjee A.L."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Tierney", "ce:indexed-name": "Tierney C."}]}, "ref-sourcetitle": "HIV Clin Trials"}}, {"ref-fulltext": "Demeter LM, Jiang H, Mukherjee AL, et al. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients. Aids. 2009;23(3):357\u2013368.", "@id": "30", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients"}, "refd-itemidlist": {"itemid": {"$": "59849103615", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "23", "@issue": "3"}, "pagerange": {"@first": "357", "@last": "368"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.M.", "@_fa": "true", "ce:surname": "Demeter", "ce:indexed-name": "Demeter L.M."}, {"@seq": "2", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Jiang", "ce:indexed-name": "Jiang H."}, {"@seq": "3", "ce:initials": "A.L.", "@_fa": "true", "ce:surname": "Mukherjee", "ce:indexed-name": "Mukherjee A.L."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR:a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med. 2004;5(5):352\u2013359.", "@id": "31", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy"}, "refd-itemidlist": {"itemid": {"$": "4644356397", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "5", "@issue": "5"}, "pagerange": {"@first": "352", "@last": "359"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Bossi", "ce:indexed-name": "Bossi P."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Peytavin", "ce:indexed-name": "Peytavin G."}, {"@seq": "3", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Ait-Mohand", "ce:indexed-name": "Ait-Mohand H."}]}, "ref-sourcetitle": "HIV Med"}}, {"ref-fulltext": "Clevenbergh P, Garraffo R, Durant J, et al. PharmAdapt:a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors:12 week results. Aids. 2002;16(17):2311\u20132315.", "@id": "32", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results"}, "refd-itemidlist": {"itemid": {"$": "0037159936", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "16", "@issue": "17"}, "pagerange": {"@first": "2311", "@last": "2315"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Clevenbergh", "ce:indexed-name": "Clevenbergh P."}, {"@seq": "2", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Garraffo", "ce:indexed-name": "Garraffo R."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Durant", "ce:indexed-name": "Durant J."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Khoo SH, Lloyd J, Dalton M, et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)\u2013a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr. 2006;41(4):461\u2013467.", "@id": "33", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)\u2013a randomized controlled trial of therapeutic drug monitoring and adherence support"}, "refd-itemidlist": {"itemid": {"$": "33646819025", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "41", "@issue": "4"}, "pagerange": {"@first": "461", "@last": "467"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.H.", "@_fa": "true", "ce:surname": "Khoo", "ce:indexed-name": "Khoo S.H."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Lloyd", "ce:indexed-name": "Lloyd J."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Dalton", "ce:indexed-name": "Dalton M."}]}, "ref-sourcetitle": "J Acquir Immune Defic Syndr"}}, {"ref-fulltext": "Liu X, Ma Q, Zhang F. Therapeutic drug monitoring in highly active antiretroviral therapy. Expert Opin Drug Saf. 2010;9(5):743\u2013758.\u2022\u2022 This article provided a comprehensive review of TDM of ARV drugs.", "@id": "34", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Therapeutic drug monitoring in highly active antiretroviral therapy"}, "refd-itemidlist": {"itemid": {"$": "77955943337", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "9", "@issue": "5"}, "pagerange": {"@first": "743", "@last": "758"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Liu", "ce:indexed-name": "Liu X."}, {"@seq": "2", "ce:initials": "Q.", "@_fa": "true", "ce:surname": "Ma", "ce:indexed-name": "Ma Q."}, {"@seq": "3", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Zhang", "ce:indexed-name": "Zhang F."}]}, "ref-sourcetitle": "Expert Opin Drug Saf"}}, {"ref-fulltext": "Pretorius E, Klinker H, Rosenkranz B. The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection. Ther Drug Monit. 2011;33(3):265\u2013274.", "@id": "35", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection"}, "refd-itemidlist": {"itemid": {"$": "80051763638", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "33", "@issue": "3"}, "pagerange": {"@first": "265", "@last": "274"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Pretorius", "ce:indexed-name": "Pretorius E."}, {"@seq": "2", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Klinker", "ce:indexed-name": "Klinker H."}, {"@seq": "3", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Rosenkranz", "ce:indexed-name": "Rosenkranz B."}]}, "ref-sourcetitle": "Ther Drug Monit"}}, {"ref-fulltext": "Morse GD, Catanzaro LM, Acosta EP. Clinical pharmacodynamics of HIV-1 protease inhibitors:use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect Dis. 2006;6(4):215\u2013225.\u2022\u2022 This article provided an excellent review of inhibitory quotient concept and its clinical applications for PIs.", "@id": "36", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy"}, "refd-itemidlist": {"itemid": {"$": "33645096370", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "6", "@issue": "4"}, "pagerange": {"@first": "215", "@last": "225"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.D.", "@_fa": "true", "ce:surname": "Morse", "ce:indexed-name": "Morse G.D."}, {"@seq": "2", "ce:initials": "L.M.", "@_fa": "true", "ce:surname": "Catanzaro", "ce:indexed-name": "Catanzaro L.M."}, {"@seq": "3", "ce:initials": "E.P.", "@_fa": "true", "ce:surname": "Acosta", "ce:indexed-name": "Acosta E.P."}]}, "ref-sourcetitle": "Lancet Infect Dis"}}, {"ref-fulltext": "Ribera E, Lopez-Cortes LF, Soriano V, et al. Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs:can they be applied to the current situation? Enferm Infecc Microbiol Clin. 2005;23(Suppl 2):41\u201367.", "@id": "37", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?"}, "refd-itemidlist": {"itemid": {"$": "34548598574", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "23"}, "pagerange": {"@first": "41", "@last": "67"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Ribera", "ce:indexed-name": "Ribera E."}, {"@seq": "2", "ce:initials": "L.F.", "@_fa": "true", "ce:surname": "Lopez-Cortes", "ce:indexed-name": "Lopez-Cortes L.F."}, {"@seq": "3", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Soriano", "ce:indexed-name": "Soriano V."}]}, "ref-sourcetitle": "Enferm Infecc Microbiol Clin"}}, {"ref-fulltext": "La Porte C. Inhibitory quotient in HIV pharmacology. Curr Opin HIV AIDS. 2008;3(3):283\u2013287.", "@id": "38", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Inhibitory quotient in HIV pharmacology"}, "refd-itemidlist": {"itemid": {"$": "42049102201", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "3", "@issue": "3"}, "pagerange": {"@first": "283", "@last": "287"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "La Porte", "ce:indexed-name": "La Porte C."}]}, "ref-sourcetitle": "Curr Opin HIV AIDS"}}, {"ref-fulltext": "Piscitelli SC. The role of therapeutic drug monitoring in the management of HIV-infected patients. Curr Infect Dis Rep. 2002;4(4):353\u2013358.", "@id": "39", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "The role of therapeutic drug monitoring in the management of HIV-infected patients"}, "refd-itemidlist": {"itemid": {"$": "0038029981", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "4", "@issue": "4"}, "pagerange": {"@first": "353", "@last": "358"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.C.", "@_fa": "true", "ce:surname": "Piscitelli", "ce:indexed-name": "Piscitelli S.C."}]}, "ref-sourcetitle": "Curr Infect Dis Rep"}}, {"ref-fulltext": "Duval X, Lamotte C, Race E, et al. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob Agents Chemother. 2002;46(2):570\u2013574.", "@id": "40", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir"}, "refd-itemidlist": {"itemid": {"$": "0036148608", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "46", "@issue": "2"}, "pagerange": {"@first": "570", "@last": "574"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Duval", "ce:indexed-name": "Duval X."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Lamotte", "ce:indexed-name": "Lamotte C."}, {"@seq": "3", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Race", "ce:indexed-name": "Race E."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Shulman N, Zolopa A, Havlir D, et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother. 2002;46(12):3907\u20133916.", "@id": "41", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia"}, "refd-itemidlist": {"itemid": {"$": "0036895440", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "46", "@issue": "12"}, "pagerange": {"@first": "3907", "@last": "3916"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Shulman", "ce:indexed-name": "Shulman N."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Zolopa", "ce:indexed-name": "Zolopa A."}, {"@seq": "3", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Havlir", "ce:indexed-name": "Havlir D."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Mallolas J, Blanco J, Labarga P, et al. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir the CIVSA study. HIV Med. 2007;8(4):226\u2013233.", "@id": "42", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir the CIVSA study"}, "refd-itemidlist": {"itemid": {"$": "34247874836", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "8", "@issue": "4"}, "pagerange": {"@first": "226", "@last": "233"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Mallolas", "ce:indexed-name": "Mallolas J."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Blanco", "ce:indexed-name": "Blanco J."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Labarga", "ce:indexed-name": "Labarga P."}]}, "ref-sourcetitle": "HIV Med"}}, {"ref-fulltext": "Molto J, Santos JR, Perez-Alvarez N, et al. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2008;52(11):3928\u20133932.", "@id": "43", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients"}, "refd-itemidlist": {"itemid": {"$": "55849125465", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "52", "@issue": "11"}, "pagerange": {"@first": "3928", "@last": "3932"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Molto", "ce:indexed-name": "Molto J."}, {"@seq": "2", "ce:initials": "J.R.", "@_fa": "true", "ce:surname": "Santos", "ce:indexed-name": "Santos J.R."}, {"@seq": "3", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Perez-Alvarez", "ce:indexed-name": "Perez-Alvarez N."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Winston A, Hales G, Amin J, et al. The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. Aids. 2005;19(13):1393\u20131399.", "@id": "44", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals"}, "refd-itemidlist": {"itemid": {"$": "29144452574", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "19", "@issue": "13"}, "pagerange": {"@first": "1393", "@last": "1399"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Winston", "ce:indexed-name": "Winston A."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Hales", "ce:indexed-name": "Hales G."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Amin", "ce:indexed-name": "Amin J."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Marcelin AG, Lamotte C, Delaugerre C, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2003;47(2):594\u2013600.", "@id": "45", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients"}, "refd-itemidlist": {"itemid": {"$": "0037308542", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "47", "@issue": "2"}, "pagerange": {"@first": "594", "@last": "600"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.G.", "@_fa": "true", "ce:surname": "Marcelin", "ce:indexed-name": "Marcelin A.G."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Lamotte", "ce:indexed-name": "Lamotte C."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Delaugerre", "ce:indexed-name": "Delaugerre C."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Barrail-Tran A, Morand-Joubert L, Poizat G, et al. Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen. Antimicrob Agents Chemother. 2008;52(5):1642\u20131646.", "@id": "46", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen"}, "refd-itemidlist": {"itemid": {"$": "42949163893", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "52", "@issue": "5"}, "pagerange": {"@first": "1642", "@last": "1646"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Barrail-Tran", "ce:indexed-name": "Barrail-Tran A."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Morand-Joubert", "ce:indexed-name": "Morand-Joubert L."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Poizat", "ce:indexed-name": "Poizat G."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Cleijsen RM, Van De Ende ME, Kroon FP, et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother. 2007;60(4):897\u2013900.", "@id": "47", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice"}, "refd-itemidlist": {"itemid": {"$": "34548784342", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "60", "@issue": "4"}, "pagerange": {"@first": "897", "@last": "900"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.M.", "@_fa": "true", "ce:surname": "Cleijsen", "ce:indexed-name": "Cleijsen R.M."}, {"@seq": "2", "ce:initials": "M.E.", "@_fa": "true", "ce:surname": "Van De Ende", "ce:indexed-name": "Van De Ende M.E."}, {"@seq": "3", "ce:initials": "F.P.", "@_fa": "true", "ce:surname": "Kroon", "ce:indexed-name": "Kroon F.P."}]}, "ref-sourcetitle": "J Antimicrob Chemother"}}, {"ref-fulltext": "Pellegrin I, Breilh D, Coureau G, et al. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients. Antimicrob Agents Chemother. 2007;51(4):1473\u20131480.", "@id": "48", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients"}, "refd-itemidlist": {"itemid": {"$": "34247147510", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "51", "@issue": "4"}, "pagerange": {"@first": "1473", "@last": "1480"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Pellegrin", "ce:indexed-name": "Pellegrin I."}, {"@seq": "2", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Breilh", "ce:indexed-name": "Breilh D."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Coureau", "ce:indexed-name": "Coureau G."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Breilh D, Pellegrin I, Rouz\u00e9s A, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). Aids. 2004;18(9):1305\u20131310.", "@id": "49", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study)"}, "refd-itemidlist": {"itemid": {"$": "3042689560", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "18", "@issue": "9"}, "pagerange": {"@first": "1305", "@last": "1310"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Breilh", "ce:indexed-name": "Breilh D."}, {"@seq": "2", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Pellegrin", "ce:indexed-name": "Pellegrin I."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Rouz\u00e9s", "ce:indexed-name": "Rouzes A."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "De Requena DG, Gallego O, Valer L, et al. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses. 2004;20(3):275\u2013278.", "@id": "50", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient"}, "refd-itemidlist": {"itemid": {"$": "12144289260", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "20", "@issue": "3"}, "pagerange": {"@first": "275", "@last": "278"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.G.", "@_fa": "true", "ce:surname": "De Requena", "ce:indexed-name": "De Requena D.G."}, {"@seq": "2", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Gallego", "ce:indexed-name": "Gallego O."}, {"@seq": "3", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Valer", "ce:indexed-name": "Valer L."}]}, "ref-sourcetitle": "AIDS Res Hum Retroviruses"}}, {"ref-fulltext": "Marcelin AG, Cohen-Codar I, King MS, et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2005;49(5):1720\u20131726.", "@id": "51", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients"}, "refd-itemidlist": {"itemid": {"$": "20944446492", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "49", "@issue": "5"}, "pagerange": {"@first": "1720", "@last": "1726"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.G.", "@_fa": "true", "ce:surname": "Marcelin", "ce:indexed-name": "Marcelin A.G."}, {"@seq": "2", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Cohen-Codar", "ce:indexed-name": "Cohen-Codar I."}, {"@seq": "3", "ce:initials": "M.S.", "@_fa": "true", "ce:surname": "King", "ce:indexed-name": "King M.S."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Torti C, Uccelli MC, Quiros-Roldan E, et al. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. J Clin Virol. 2006;35(4):414\u2013419.", "@id": "52", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors"}, "refd-itemidlist": {"itemid": {"$": "33644637513", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "35", "@issue": "4"}, "pagerange": {"@first": "414", "@last": "419"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Torti", "ce:indexed-name": "Torti C."}, {"@seq": "2", "ce:initials": "M.C.", "@_fa": "true", "ce:surname": "Uccelli", "ce:indexed-name": "Uccelli M.C."}, {"@seq": "3", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Quiros-Roldan", "ce:indexed-name": "Quiros-Roldan E."}]}, "ref-sourcetitle": "J Clin Virol"}}, {"ref-fulltext": "Gianotti N, Galli L, Danise A, et al. Ability of different lopinavir genotypic inhibitory quotients to predict 48\u2010week virological response in highly treatment\u2010experienced HIV\u2010infected patients receiving lopinavir/ritonavir. J Med Virol. 2006;78(12):1537\u20131541.", "@id": "53", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Ability of different lopinavir genotypic inhibitory quotients to predict 48\u2010week virological response in highly treatment\u2010experienced HIV\u2010infected patients receiving lopinavir/ritonavir"}, "refd-itemidlist": {"itemid": {"$": "33750546218", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "78", "@issue": "12"}, "pagerange": {"@first": "1537", "@last": "1541"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Gianotti", "ce:indexed-name": "Gianotti N."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Galli", "ce:indexed-name": "Galli L."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Danise", "ce:indexed-name": "Danise A."}]}, "ref-sourcetitle": "J Med Virol"}}, {"ref-fulltext": "Maillard A, Chapplain J-M, Tribut O, et al. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir\u2013ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients. J Clin Virol. 2007;38(2):131\u2013138.", "@id": "54", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir\u2013ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients"}, "refd-itemidlist": {"itemid": {"$": "33846117422", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "38", "@issue": "2"}, "pagerange": {"@first": "131", "@last": "138"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Maillard", "ce:indexed-name": "Maillard A."}, {"@seq": "2", "ce:initials": "J.-M.", "@_fa": "true", "ce:surname": "Chapplain", "ce:indexed-name": "Chapplain J.-M."}, {"@seq": "3", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Tribut", "ce:indexed-name": "Tribut O."}]}, "ref-sourcetitle": "J Clin Virol"}}, {"ref-fulltext": "Marcelin AG, Dalban C, Peytavin G, et al. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2004;48(12):4687\u20134692.", "@id": "55", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients"}, "refd-itemidlist": {"itemid": {"$": "9644272512", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "48", "@issue": "12"}, "pagerange": {"@first": "4687", "@last": "4692"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.G.", "@_fa": "true", "ce:surname": "Marcelin", "ce:indexed-name": "Marcelin A.G."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Dalban", "ce:indexed-name": "Dalban C."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Peytavin", "ce:indexed-name": "Peytavin G."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Valer L, De Mendoza C, Soriano V. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. J Med Virol. 2005;77(4):460\u2013464.", "@id": "56", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients"}, "refd-itemidlist": {"itemid": {"$": "27744600007", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "77", "@issue": "4"}, "pagerange": {"@first": "460", "@last": "464"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Valer", "ce:indexed-name": "Valer L."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "De Mendoza", "ce:indexed-name": "De Mendoza C."}, {"@seq": "3", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Soriano", "ce:indexed-name": "Soriano V."}]}, "ref-sourcetitle": "J Med Virol"}}, {"ref-fulltext": "De Requena DG, Bonora S, Calcagno A, et al. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. Antimicrob Agents Chemother. 2008;52(3):1066\u20131071.", "@id": "57", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens"}, "refd-itemidlist": {"itemid": {"$": "40549125612", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "52", "@issue": "3"}, "pagerange": {"@first": "1066", "@last": "1071"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.G.", "@_fa": "true", "ce:surname": "De Requena", "ce:indexed-name": "De Requena D.G."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Bonora", "ce:indexed-name": "Bonora S."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Calcagno", "ce:indexed-name": "Calcagno A."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "De Requena DG, Bonora S, Vigan\u00f2 O, et al. Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. J Antimicrob Chemother. 2011;66(1):192\u2013200.", "@id": "58", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens"}, "refd-itemidlist": {"itemid": {"$": "78650322209", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "66", "@issue": "1"}, "pagerange": {"@first": "192", "@last": "200"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.G.", "@_fa": "true", "ce:surname": "De Requena", "ce:indexed-name": "De Requena D.G."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Bonora", "ce:indexed-name": "Bonora S."}, {"@seq": "3", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Vigan\u00f2", "ce:indexed-name": "Vigano O."}]}, "ref-sourcetitle": "J Antimicrob Chemother"}}, {"ref-fulltext": "Molt\u00f3 J, Valle M, Santos JR, et al. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients. Antivir Ther. 2010;15(2):219\u2013225.\u2022\u2022 This article provided an example of the application of IQ concept for modification of darunavir/ritonavir dosage regimen.", "@id": "59", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients"}, "refd-itemidlist": {"itemid": {"$": "77950674480", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "15", "@issue": "2"}, "pagerange": {"@first": "219", "@last": "225"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Molt\u00f3", "ce:indexed-name": "Molto J."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Valle", "ce:indexed-name": "Valle M."}, {"@seq": "3", "ce:initials": "J.R.", "@_fa": "true", "ce:surname": "Santos", "ce:indexed-name": "Santos J.R."}]}, "ref-sourcetitle": "Antivir Ther"}}, {"ref-fulltext": "Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1:24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354\u2013362.", "@id": "60", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study"}, "refd-itemidlist": {"itemid": {"$": "84898987717", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "210", "@issue": "3"}, "pagerange": {"@first": "354", "@last": "362"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Castagna", "ce:indexed-name": "Castagna A."}, {"@seq": "2", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Maggiolo", "ce:indexed-name": "Maggiolo F."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Penco", "ce:indexed-name": "Penco G."}]}, "ref-sourcetitle": "J Infect Dis"}}, {"ref-fulltext": "D\u2019Avolio A, Pensi D, Baietto L, et al. Therapeutic drug monitoring of intracellular anti-infective agents. J Pharm Biomed Anal. 2014;101:183\u2013193.", "@id": "61", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Therapeutic drug monitoring of intracellular anti-infective agents"}, "refd-itemidlist": {"itemid": {"$": "84908318488", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "101"}, "pagerange": {"@first": "183", "@last": "193"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "D\u2019Avolio", "ce:indexed-name": "D'Avolio A."}, {"@seq": "2", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Pensi", "ce:indexed-name": "Pensi D."}, {"@seq": "3", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Baietto", "ce:indexed-name": "Baietto L."}]}, "ref-sourcetitle": "J Pharm Biomed Anal"}}, {"ref-fulltext": "Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197(1):102\u2013108.", "@id": "62", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy"}, "refd-itemidlist": {"itemid": {"$": "39349112711", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "197", "@issue": "1"}, "pagerange": {"@first": "102", "@last": "108"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Goicoechea", "ce:indexed-name": "Goicoechea M."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Liu", "ce:indexed-name": "Liu S."}, {"@seq": "3", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Best", "ce:indexed-name": "Best B."}]}, "ref-sourcetitle": "J Infect Dis"}}, {"ref-fulltext": "Rodriguez-Novoa S, Labarga P, D\u2019Avolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. Aids. 2010;24(7):1064\u20131066.", "@id": "63", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations"}, "refd-itemidlist": {"itemid": {"$": "77950925935", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "24", "@issue": "7"}, "pagerange": {"@first": "1064", "@last": "1066"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Rodriguez-Novoa", "ce:indexed-name": "Rodriguez-Novoa S."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Labarga", "ce:indexed-name": "Labarga P."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "D\u2019Avolio", "ce:indexed-name": "D'Avolio A."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Avihingsanon A, Sophonphan J, Thammajaruk N, et al. Plasma tenofovir concentrations and proximal tubular dysfunction in HIV-infected adults receiving tenofovir in Thailand. J AIDS Clin Res. 2015;6(7):1\u20137.", "@id": "64", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Plasma tenofovir concentrations and proximal tubular dysfunction in HIV-infected adults receiving tenofovir in Thailand"}, "refd-itemidlist": {"itemid": {"$": "84996615218", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "6", "@issue": "7"}, "pagerange": {"@first": "1", "@last": "7"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Avihingsanon", "ce:indexed-name": "Avihingsanon A."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Sophonphan", "ce:indexed-name": "Sophonphan J."}, {"@seq": "3", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Thammajaruk", "ce:indexed-name": "Thammajaruk N."}]}, "ref-sourcetitle": "J AIDS Clin Res"}}, {"ref-fulltext": "Usach I, Melis V, Peris JE. Non-nucleoside reverse transcriptase inhibitors:a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc. 2013;16:1\u201314.", "@id": "65", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability"}, "refd-itemidlist": {"itemid": {"$": "84891550941", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "16"}, "pagerange": {"@first": "1", "@last": "14"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Usach", "ce:indexed-name": "Usach I."}, {"@seq": "2", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Melis", "ce:indexed-name": "Melis V."}, {"@seq": "3", "ce:initials": "J.E.", "@_fa": "true", "ce:surname": "Peris", "ce:indexed-name": "Peris J.E."}]}, "ref-sourcetitle": "J Int AIDS Soc"}}, {"ref-fulltext": "Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. Aids. 2001;15(1):71\u201375.", "@id": "66", "ref-info": {"ref-publicationyear": {"@first": "2001"}, "ref-title": {"ref-titletext": "Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients"}, "refd-itemidlist": {"itemid": {"$": "0035808574", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "15", "@issue": "1"}, "pagerange": {"@first": "71", "@last": "75"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Marzolini", "ce:indexed-name": "Marzolini C."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Telenti", "ce:indexed-name": "Telenti A."}, {"@seq": "3", "ce:initials": "L.A.", "@_fa": "true", "ce:surname": "Decosterd", "ce:indexed-name": "Decosterd L.A."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Group ES. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily:96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015;15(7):793\u2013802.\u2022\u2022 The ENCORE1 study results showed efavirenz 400 mg daily is non-inferior to 600 mg daily when efavirenz was given in combination with tenofovir and emtricitabine.", "@id": "67", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study"}, "refd-itemidlist": {"itemid": {"$": "84937512973", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "15", "@issue": "7"}, "pagerange": {"@first": "793", "@last": "802"}}, "ref-authors": {"collaboration": {"@seq": "1", "ce:text": "Group ES", "ce:indexed-name": "Group ES"}}, "ref-sourcetitle": "Lancet Infect Dis"}}, {"ref-fulltext": "Dickinson L, Amin J, Else L, et al. Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400 mg vs. 600 mg) in treatment-naive HIV-infected patients:results of the ENCORE1 study. Clin Pharmacol Ther. 2015;98(4):406\u2013416.\u2022\u2022 This study showed a higher proportion of patients receiving 400 mg/day of efavirenz having concentration at 24 h post-dose of <1 mg/L compared to 600 mg/day while both groups had comparable viral suppression.", "@id": "68", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400 mg vs. 600 mg) in treatment-naive HIV-infected patients: results of the ENCORE1 study"}, "refd-itemidlist": {"itemid": {"$": "84952787102", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "98", "@issue": "4"}, "pagerange": {"@first": "406", "@last": "416"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Dickinson", "ce:indexed-name": "Dickinson L."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Amin", "ce:indexed-name": "Amin J."}, {"@seq": "3", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Else", "ce:indexed-name": "Else L."}]}, "ref-sourcetitle": "Clin Pharmacol Ther"}}, {"ref-fulltext": "Calcagno A, Marinaro L, Nozza S, et al. Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. Antiviral Res. 2014;108:44\u201347.", "@id": "69", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients"}, "refd-itemidlist": {"itemid": {"$": "84902003904", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "108"}, "pagerange": {"@first": "44", "@last": "47"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Calcagno", "ce:indexed-name": "Calcagno A."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Marinaro", "ce:indexed-name": "Marinaro L."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Nozza", "ce:indexed-name": "Nozza S."}]}, "ref-sourcetitle": "Antiviral Res"}}, {"ref-fulltext": "Lv Z, Chu Y, Wang Y. HIV protease inhibitors:a review of molecular selectivity and toxicity. HIV AIDS (Auckl). 2015;7:95\u2013104.", "@id": "70", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "HIV protease inhibitors: a review of molecular selectivity and toxicity"}, "refd-itemidlist": {"itemid": {"$": "84930672138", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "7"}, "pagerange": {"@first": "95", "@last": "104"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "Z.", "@_fa": "true", "ce:surname": "Lv", "ce:indexed-name": "Lv Z."}, {"@seq": "2", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Chu", "ce:indexed-name": "Chu Y."}, {"@seq": "3", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Wang", "ce:indexed-name": "Wang Y."}]}, "ref-sourcetitle": "HIV AIDS (Auckl)"}}, {"ref-fulltext": "De Nicolo A, Simiele M, Calcagno A, et al. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens. Antimicrob Agents Chemother. 2014;58(7):4042\u20134047.", "@id": "71", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens"}, "refd-itemidlist": {"itemid": {"$": "84903174062", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "58", "@issue": "7"}, "pagerange": {"@first": "4042", "@last": "4047"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "De Nicolo", "ce:indexed-name": "De Nicolo A."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Simiele", "ce:indexed-name": "Simiele M."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Calcagno", "ce:indexed-name": "Calcagno A."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53(1):4\u20139.", "@id": "72", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients"}, "refd-itemidlist": {"itemid": {"$": "0346025675", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "53", "@issue": "1"}, "pagerange": {"@first": "4", "@last": "9"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.K.", "@_fa": "true", "ce:surname": "Zeldin", "ce:indexed-name": "Zeldin R.K."}, {"@seq": "2", "ce:initials": "R.A.", "@_fa": "true", "ce:surname": "Petruschke", "ce:indexed-name": "Petruschke R.A."}]}, "ref-sourcetitle": "J Antimicrob Chemother"}}, {"ref-fulltext": "Cooper CL, Van Heeswijk RP, Gallicano K, et al. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003;36(12):1585\u20131592.", "@id": "73", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "A review of low-dose ritonavir in protease inhibitor combination therapy"}, "refd-itemidlist": {"itemid": {"$": "0037871892", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "36", "@issue": "12"}, "pagerange": {"@first": "1585", "@last": "1592"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.L.", "@_fa": "true", "ce:surname": "Cooper", "ce:indexed-name": "Cooper C.L."}, {"@seq": "2", "ce:initials": "R.P.", "@_fa": "true", "ce:surname": "Van Heeswijk", "ce:indexed-name": "Van Heeswijk R.P."}, {"@seq": "3", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Gallicano", "ce:indexed-name": "Gallicano K."}]}, "ref-sourcetitle": "Clin Infect Dis"}}, {"ref-fulltext": "Mathias A, German P, Murray B, et al. Pharmacokinetics and pharmacodynamics of GS\u20109350:a novel pharmacokinetic enhancer without anti\u2010HIV activity. Clin Pharmacol Ther. 2010;87(3):322\u2013329.", "@id": "74", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Pharmacokinetics and pharmacodynamics of GS\u20109350: a novel pharmacokinetic enhancer without anti\u2010HIV activity"}, "refd-itemidlist": {"itemid": {"$": "77149123315", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "87", "@issue": "3"}, "pagerange": {"@first": "322", "@last": "329"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Mathias", "ce:indexed-name": "Mathias A."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "German", "ce:indexed-name": "German P."}, {"@seq": "3", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Murray", "ce:indexed-name": "Murray B."}]}, "ref-sourcetitle": "Clin Pharmacol Ther"}}, {"ref-fulltext": "Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1\u2013infected patients:week 48 results. J Infect Dis. 2013;208(1):32\u201339.", "@id": "75", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1\u2013infected patients: week 48 results"}, "refd-itemidlist": {"itemid": {"$": "84878525908", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "208", "@issue": "1"}, "pagerange": {"@first": "32", "@last": "39"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.E.", "@_fa": "true", "ce:surname": "Gallant", "ce:indexed-name": "Gallant J.E."}, {"@seq": "2", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Koenig", "ce:indexed-name": "Koenig E."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Andrade-Villanueva", "ce:indexed-name": "Andrade-Villanueva J."}]}, "ref-sourcetitle": "J Infect Dis"}}, {"ref-fulltext": "Kakuda TN, Opsomer M, Timmers M, et al. Pharmacokinetics of darunavir in fixed\u2010dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. J Clin Pharmacol. 2014;54(8):949\u2013957.", "@id": "76", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Pharmacokinetics of darunavir in fixed\u2010dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers"}, "refd-itemidlist": {"itemid": {"$": "84901063270", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "54", "@issue": "8"}, "pagerange": {"@first": "949", "@last": "957"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.N.", "@_fa": "true", "ce:surname": "Kakuda", "ce:indexed-name": "Kakuda T.N."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Opsomer", "ce:indexed-name": "Opsomer M."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Timmers", "ce:indexed-name": "Timmers M."}]}, "ref-sourcetitle": "J Clin Pharmacol"}}, {"ref-fulltext": "Marzolini C, Gibbons S, Khoo S, et al. Cobicistat versus ritonavir boosting and differences in the drug\u2013drug interaction profiles with co-medications. J Antimicrob Chemother. 2016;71(7):1755\u20131758.", "@id": "77", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Cobicistat versus ritonavir boosting and differences in the drug\u2013drug interaction profiles with co-medications"}, "refd-itemidlist": {"itemid": {"$": "84979084522", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "71", "@issue": "7"}, "pagerange": {"@first": "1755", "@last": "1758"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Marzolini", "ce:indexed-name": "Marzolini C."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Gibbons", "ce:indexed-name": "Gibbons S."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Khoo", "ce:indexed-name": "Khoo S."}]}, "ref-sourcetitle": "J Antimicrob Chemother"}}, {"ref-fulltext": "Crutchley RD, Guduru RC, Cheng AM. Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection. HIV/AIDS (Auckland, NZ). 2016;8:47.", "@id": "78", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection"}, "refd-itemidlist": {"itemid": {"$": "84961258665", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "8"}, "pagerange": {"@first": "47"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.D.", "@_fa": "true", "ce:surname": "Crutchley", "ce:indexed-name": "Crutchley R.D."}, {"@seq": "2", "ce:initials": "R.C.", "@_fa": "true", "ce:surname": "Guduru", "ce:indexed-name": "Guduru R.C."}, {"@seq": "3", "ce:initials": "A.M.", "@_fa": "true", "ce:surname": "Cheng", "ce:indexed-name": "Cheng A.M."}]}, "ref-sourcetitle": "HIV/AIDS (Auckland, NZ)"}}, {"ref-fulltext": "Fabbiani M, Di Giambenedetto S, Ragazzoni E, et al. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. HIV Med. 2010;11(5):326\u2013333.", "@id": "79", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection"}, "refd-itemidlist": {"itemid": {"$": "77953165375", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "11", "@issue": "5"}, "pagerange": {"@first": "326", "@last": "333"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Fabbiani", "ce:indexed-name": "Fabbiani M."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Di Giambenedetto", "ce:indexed-name": "Di Giambenedetto S."}, {"@seq": "3", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Ragazzoni", "ce:indexed-name": "Ragazzoni E."}]}, "ref-sourcetitle": "HIV Med"}}, {"ref-fulltext": "Duval X, Mentre F, Rey E, et al. Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen\u2013ANRS 111 trial. Fundam Clin Pharmacol. 2009;23(4):491\u2013500.", "@id": "80", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen\u2013ANRS 111 trial"}, "refd-itemidlist": {"itemid": {"$": "67649088607", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "23", "@issue": "4"}, "pagerange": {"@first": "491", "@last": "500"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Duval", "ce:indexed-name": "Duval X."}, {"@seq": "2", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Mentre", "ce:indexed-name": "Mentre F."}, {"@seq": "3", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Rey", "ce:indexed-name": "Rey E."}]}, "ref-sourcetitle": "Fundam Clin Pharmacol"}}, {"ref-fulltext": "Duval X, Peytavin G, Albert I, et al. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients. HIV Med. 2004;5(4):307\u2013313.", "@id": "81", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients"}, "refd-itemidlist": {"itemid": {"$": "4043131673", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "5", "@issue": "4"}, "pagerange": {"@first": "307", "@last": "313"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Duval", "ce:indexed-name": "Duval X."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Peytavin", "ce:indexed-name": "Peytavin G."}, {"@seq": "3", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Albert", "ce:indexed-name": "Albert I."}]}, "ref-sourcetitle": "HIV Med"}}, {"ref-fulltext": "Casado JL, Moreno S, Hertogs K, et al. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. Aids. 2002;16(1):47\u201352.", "@id": "82", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen"}, "refd-itemidlist": {"itemid": {"$": "0037016433", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "16", "@issue": "1"}, "pagerange": {"@first": "47", "@last": "52"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.L.", "@_fa": "true", "ce:surname": "Casado", "ce:indexed-name": "Casado J.L."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Moreno", "ce:indexed-name": "Moreno S."}, {"@seq": "3", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Hertogs", "ce:indexed-name": "Hertogs K."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Falkensammer B, Fasser W, Scherer K, et al. Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1. Int J Immunopathol Pharmacol. 2005;18(1):145\u2013154.", "@id": "83", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1"}, "refd-itemidlist": {"itemid": {"$": "14844288012", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "18", "@issue": "1"}, "pagerange": {"@first": "145", "@last": "154"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Falkensammer", "ce:indexed-name": "Falkensammer B."}, {"@seq": "2", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Fasser", "ce:indexed-name": "Fasser W."}, {"@seq": "3", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Scherer", "ce:indexed-name": "Scherer K."}]}, "ref-sourcetitle": "Int J Immunopathol Pharmacol"}}, {"ref-fulltext": "Lotsch J, Harder S, Sturmer M, et al. Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007;51(9):3264\u20133272.", "@id": "84", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1"}, "refd-itemidlist": {"itemid": {"$": "35948968734", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "51", "@issue": "9"}, "pagerange": {"@first": "3264", "@last": "3272"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Lotsch", "ce:indexed-name": "Lotsch J."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Harder", "ce:indexed-name": "Harder S."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Sturmer", "ce:indexed-name": "Sturmer M."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Sadler BM, Gillotin C, Lou Y, et al. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother. 2001;45(1):30\u201337.", "@id": "85", "ref-info": {"ref-publicationyear": {"@first": "2001"}, "ref-title": {"ref-titletext": "Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing"}, "refd-itemidlist": {"itemid": {"$": "0035174709", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "45", "@issue": "1"}, "pagerange": {"@first": "30", "@last": "37"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.M.", "@_fa": "true", "ce:surname": "Sadler", "ce:indexed-name": "Sadler B.M."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Gillotin", "ce:indexed-name": "Gillotin C."}, {"@seq": "3", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Lou", "ce:indexed-name": "Lou Y."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Gorowara M, Burger D, Hill A, et al. Pharmacokinetics of low-dose protease inhibitors and efavirenz in low-and middle-income countries. Curr Opin HIV AIDS. 2010;5(1):90\u201396.", "@id": "86", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Pharmacokinetics of low-dose protease inhibitors and efavirenz in low-and middle-income countries"}, "refd-itemidlist": {"itemid": {"$": "74349123323", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "5", "@issue": "1"}, "pagerange": {"@first": "90", "@last": "96"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Gorowara", "ce:indexed-name": "Gorowara M."}, {"@seq": "2", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Burger", "ce:indexed-name": "Burger D."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Hill", "ce:indexed-name": "Hill A."}]}, "ref-sourcetitle": "Curr Opin HIV AIDS"}}, {"ref-fulltext": "Avihingsanon A, Lugt J, Kerr S, et al. A low dose of ritonavir\u2010boosted atazanavir provides adequate pharmacokinetic parameters in HIV\u20101\u2010infected Thai adults. Clin Pharmacol Ther. 2009;85(4):402\u2013408.\u2022 This study provides evidence that Thai patients may require a lower than standard dose of atazanavir/ritonavir.", "@id": "87", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "A low dose of ritonavir\u2010boosted atazanavir provides adequate pharmacokinetic parameters in HIV\u20101\u2010infected Thai adults"}, "refd-itemidlist": {"itemid": {"$": "62649107112", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "85", "@issue": "4"}, "pagerange": {"@first": "402", "@last": "408"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Avihingsanon", "ce:indexed-name": "Avihingsanon A."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Lugt", "ce:indexed-name": "Lugt J."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Kerr", "ce:indexed-name": "Kerr S."}]}, "ref-sourcetitle": "Clin Pharmacol Ther"}}, {"ref-fulltext": "Boyd M, Mootsikapun P, Burger D, et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir Ther. 2005;10(2):301\u2013307.\u2022 Reduced dose of indinavir/ritonavir provides adequate exposure of indinavir and sufficient.", "@id": "88", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients"}, "refd-itemidlist": {"itemid": {"$": "22844448412", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "10", "@issue": "2"}, "pagerange": {"@first": "301", "@last": "307"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Boyd", "ce:indexed-name": "Boyd M."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Mootsikapun", "ce:indexed-name": "Mootsikapun P."}, {"@seq": "3", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Burger", "ce:indexed-name": "Burger D."}]}, "ref-sourcetitle": "Antivir Ther"}}, {"ref-fulltext": "Acosta EP, Kakuda TN, Brundage RC, et al. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 2000;30(Suppl 2):S151\u2013159.", "@id": "89", "ref-info": {"ref-publicationyear": {"@first": "2000"}, "ref-title": {"ref-titletext": "Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors"}, "refd-itemidlist": {"itemid": {"$": "0034458321", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "30"}, "pagerange": {"@first": "S151", "@last": "S159"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.P.", "@_fa": "true", "ce:surname": "Acosta", "ce:indexed-name": "Acosta E.P."}, {"@seq": "2", "ce:initials": "T.N.", "@_fa": "true", "ce:surname": "Kakuda", "ce:indexed-name": "Kakuda T.N."}, {"@seq": "3", "ce:initials": "R.C.", "@_fa": "true", "ce:surname": "Brundage", "ce:indexed-name": "Brundage R.C."}]}, "ref-sourcetitle": "Clin Infect Dis"}}, {"ref-fulltext": "Boffito M, Jackson A, Amara A, et al. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation. Antimicrob Agents Chemother. 2011;55(9):4218\u20134223.", "@id": "90", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation"}, "refd-itemidlist": {"itemid": {"$": "80051804579", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "55", "@issue": "9"}, "pagerange": {"@first": "4218", "@last": "4223"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Boffito", "ce:indexed-name": "Boffito M."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Jackson", "ce:indexed-name": "Jackson A."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Amara", "ce:indexed-name": "Amara A."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection:a review. Ther Clin Risk Manag. 2008;4(5):1023\u20131033.", "@id": "91", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Lopinavir/ritonavir in the treatment of HIV-1 infection: a review"}, "refd-itemidlist": {"itemid": {"$": "56749117743", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "4", "@issue": "5"}, "pagerange": {"@first": "1023", "@last": "1033"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Chandwani", "ce:indexed-name": "Chandwani A."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Shuter", "ce:indexed-name": "Shuter J."}]}, "ref-sourcetitle": "Ther Clin Risk Manag"}}, {"ref-fulltext": "Edward P, Acosta J, Daniel R. Antiretroviral pharmacokinetics, resistance testing, and therapeutic drug monitoring. In:Libman H, Makadon HJ, editors. HIV. United States:Philadelphia American College of Physicians; 2007. p. 115\u2013136.", "@id": "92", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Antiretroviral pharmacokinetics, resistance testing, and therapeutic drug monitoring"}, "refd-itemidlist": {"itemid": {"$": "84996831994", "@idtype": "SGR"}}, "ref-volisspag": {"pagerange": {"@first": "115", "@last": "136"}}, "ref-text": "Libman H., Makadon H.J., (eds), United States: Philadelphia American College of Physicians", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Edward", "ce:indexed-name": "Edward P."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Acosta", "ce:indexed-name": "Acosta J."}, {"@seq": "3", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Daniel", "ce:indexed-name": "Daniel R."}]}, "ref-sourcetitle": "HIV"}}, {"ref-fulltext": "Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther. 2014;19(4):262\u2013276.", "@id": "93", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Developmental pharmacokinetics in pediatric populations"}, "refd-itemidlist": {"itemid": {"$": "84978003056", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "19", "@issue": "4"}, "pagerange": {"@first": "262", "@last": "276"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Lu", "ce:indexed-name": "Lu H."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Rosenbaum", "ce:indexed-name": "Rosenbaum S."}]}, "ref-sourcetitle": "J Pediatr Pharmacol Ther"}}, {"ref-fulltext": "Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants:part I. Clin Pharmacokinet. 2002;41(12):959\u2013998.", "@id": "94", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "Ontogeny of hepatic and renal systemic clearance pathways in infants: part I"}, "refd-itemidlist": {"itemid": {"$": "0036396419", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "41", "@issue": "12"}, "pagerange": {"@first": "959", "@last": "998"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Alcorn", "ce:indexed-name": "Alcorn J."}, {"@seq": "2", "ce:initials": "P.J.", "@_fa": "true", "ce:surname": "McNamara", "ce:indexed-name": "McNamara P.J."}]}, "ref-sourcetitle": "Clin Pharmacokinet"}}, {"ref-fulltext": "L\u2019Homme R, Warris A, Gibb D, et al. Children with HIV are not small adults:what is different in pharmacology? Curr Opin HIV AIDS. 2007;2(5):405\u2013409.", "@id": "95", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Children with HIV are not small adults: what is different in pharmacology?"}, "refd-itemidlist": {"itemid": {"$": "34547913838", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "2", "@issue": "5"}, "pagerange": {"@first": "405", "@last": "409"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.", "@_fa": "true", "ce:surname": "L\u2019Homme", "ce:indexed-name": "L'Homme R."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Warris", "ce:indexed-name": "Warris A."}, {"@seq": "3", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Gibb", "ce:indexed-name": "Gibb D."}]}, "ref-sourcetitle": "Curr Opin HIV AIDS"}}, {"ref-fulltext": "Hirt D, Urien S, Jullien V, et al. Age-related effects on nelfinavir and M8 pharmacokinetics:a population study with 182 children. Antimicrob Agents Chemother. 2006;50(3):910\u2013916.", "@id": "96", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children"}, "refd-itemidlist": {"itemid": {"$": "33644649891", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "50", "@issue": "3"}, "pagerange": {"@first": "910", "@last": "916"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Hirt", "ce:indexed-name": "Hirt D."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Urien", "ce:indexed-name": "Urien S."}, {"@seq": "3", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Jullien", "ce:indexed-name": "Jullien V."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Guidelines for the use of antiretroviral agents in pediatrics HIV infection. 2016. [cited 2016 Mar]. Available from:https://aidsinfo.nih.gov/", "@id": "97", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-website": {"ce:e-address": {"$": "https://aidsinfo.nih.gov/", "@type": "email"}}, "refd-itemidlist": {"itemid": {"$": "79953060644", "@idtype": "SGR"}}, "ref-text": "Available from, Mar", "ref-sourcetitle": "Guidelines for the use of antiretroviral agents in pediatrics HIV infection"}}, {"ref-fulltext": "Jullien V, Urien S, Hirt D, et al. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother. 2006;50(11):3548\u20133555.", "@id": "98", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years"}, "refd-itemidlist": {"itemid": {"$": "33750594232", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "50", "@issue": "11"}, "pagerange": {"@first": "3548", "@last": "3555"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Jullien", "ce:indexed-name": "Jullien V."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Urien", "ce:indexed-name": "Urien S."}, {"@seq": "3", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Hirt", "ce:indexed-name": "Hirt D."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Verweel G, Burger DM, Sheehan NL, et al. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below. Antivir Ther. 2007;12(4):453\u2013458.", "@id": "99", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below"}, "refd-itemidlist": {"itemid": {"$": "34447283563", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "12", "@issue": "4"}, "pagerange": {"@first": "453", "@last": "458"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Verweel", "ce:indexed-name": "Verweel G."}, {"@seq": "2", "ce:initials": "D.M.", "@_fa": "true", "ce:surname": "Burger", "ce:indexed-name": "Burger D.M."}, {"@seq": "3", "ce:initials": "N.L.", "@_fa": "true", "ce:surname": "Sheehan", "ce:indexed-name": "Sheehan N.L."}]}, "ref-sourcetitle": "Antivir Ther"}}, {"ref-fulltext": "Nikanjam M, Kabamba D, Cressey TR, et al. Nevirapine exposure with WHO pediatric weight band dosing:enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob Agents Chemother. 2012;56(10):5374\u20135380.\u2022 A population pharmacokinetic study of nevirapine in children was developed from 639 infants, children, and adolescents. Age, CYP2B6 genotype, and ritonavir were independent predictors of nevirapine oral clearance.", "@id": "100", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience"}, "refd-itemidlist": {"itemid": {"$": "84866307391", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "56", "@issue": "10"}, "pagerange": {"@first": "5374", "@last": "5380"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Nikanjam", "ce:indexed-name": "Nikanjam M."}, {"@seq": "2", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Kabamba", "ce:indexed-name": "Kabamba D."}, {"@seq": "3", "ce:initials": "T.R.", "@_fa": "true", "ce:surname": "Cressey", "ce:indexed-name": "Cressey T.R."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine:pharmacokinetic considerations in children and pregnant women. Clin Pharmacokinet. 2000;39(4):281\u2013293.", "@id": "101", "ref-info": {"ref-publicationyear": {"@first": "2000"}, "ref-title": {"ref-titletext": "Nevirapine: pharmacokinetic considerations in children and pregnant women"}, "refd-itemidlist": {"itemid": {"$": "0033760913", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "39", "@issue": "4"}, "pagerange": {"@first": "281", "@last": "293"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Mirochnick", "ce:indexed-name": "Mirochnick M."}, {"@seq": "2", "ce:initials": "D.F.", "@_fa": "true", "ce:surname": "Clarke", "ce:indexed-name": "Clarke D.F."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Dorenbaum", "ce:indexed-name": "Dorenbaum A."}]}, "ref-sourcetitle": "Clin Pharmacokinet"}}, {"ref-fulltext": "Tiemessen CT, Kuhn L. Immune pathogenesis of pediatric HIV-1 infection. Curr HIV/AIDS Rep. 2006;3(1):13\u201319.", "@id": "102", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Immune pathogenesis of pediatric HIV-1 infection"}, "refd-itemidlist": {"itemid": {"$": "33646446651", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "3", "@issue": "1"}, "pagerange": {"@first": "13", "@last": "19"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.T.", "@_fa": "true", "ce:surname": "Tiemessen", "ce:indexed-name": "Tiemessen C.T."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Kuhn", "ce:indexed-name": "Kuhn L."}]}, "ref-sourcetitle": "Curr HIV/AIDS Rep"}}, {"ref-fulltext": "Burger DM. The role of therapeutic drug monitoring in pediatric HIV/AIDS. Ther Drug Monit. 2010;32(3):269\u2013272.", "@id": "103", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "The role of therapeutic drug monitoring in pediatric HIV/AIDS"}, "refd-itemidlist": {"itemid": {"$": "77952952136", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "32", "@issue": "3"}, "pagerange": {"@first": "269", "@last": "272"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.M.", "@_fa": "true", "ce:surname": "Burger", "ce:indexed-name": "Burger D.M."}]}, "ref-sourcetitle": "Ther Drug Monit"}}, {"ref-fulltext": "Schulte J, Dominguez K, Sukalac T, et al. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs:pediatric spectrum of HIV disease, 1989-2004. Pediatrics. 2007;119(4):E900\u20136.", "@id": "104", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989-2004"}, "refd-itemidlist": {"itemid": {"$": "34147120217", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "119", "@issue": "4"}, "pagerange": {"@first": "E900", "@last": "E906"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Schulte", "ce:indexed-name": "Schulte J."}, {"@seq": "2", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Dominguez", "ce:indexed-name": "Dominguez K."}, {"@seq": "3", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Sukalac", "ce:indexed-name": "Sukalac T."}]}, "ref-sourcetitle": "Pediatrics"}}, {"ref-fulltext": "Buckoreelall K, Cressey TR, King JR. Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet. 2012;51(10):639\u2013659.", "@id": "105", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Pharmacokinetic optimization of antiretroviral therapy in pregnancy"}, "refd-itemidlist": {"itemid": {"$": "84873466060", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "51", "@issue": "10"}, "pagerange": {"@first": "639", "@last": "659"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Buckoreelall", "ce:indexed-name": "Buckoreelall K."}, {"@seq": "2", "ce:initials": "T.R.", "@_fa": "true", "ce:surname": "Cressey", "ce:indexed-name": "Cressey T.R."}, {"@seq": "3", "ce:initials": "J.R.", "@_fa": "true", "ce:surname": "King", "ce:indexed-name": "King J.R."}]}, "ref-sourcetitle": "Clin Pharmacokinet"}}, {"ref-fulltext": "Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol. 2015;39(7):512\u2013519.", "@id": "106", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Pharmacokinetics of drugs in pregnancy"}, "refd-itemidlist": {"itemid": {"$": "84945131769", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "39", "@issue": "7"}, "pagerange": {"@first": "512", "@last": "519"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Feghali", "ce:indexed-name": "Feghali M."}, {"@seq": "2", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Venkataramanan", "ce:indexed-name": "Venkataramanan R."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Caritis", "ce:indexed-name": "Caritis S."}]}, "ref-sourcetitle": "Semin Perinatol"}}, {"ref-fulltext": "Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014;5(65):1\u20135.", "@id": "107", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Physiologic and pharmacokinetic changes in pregnancy"}, "refd-itemidlist": {"itemid": {"$": "84901035355", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "5", "@issue": "65"}, "pagerange": {"@first": "1", "@last": "5"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.M.", "@_fa": "true", "ce:surname": "Costantine", "ce:indexed-name": "Costantine M.M."}]}, "ref-sourcetitle": "Front Pharmacol"}}, {"ref-fulltext": "Maher JE, Goldenberg RL, Tamura T, et al. Albumin levels in pregnancy:a hypothesis\u2013decreased levels of albumin are related to increased levels of alpha-fetoprotein. Early Hum Dev. 1993;34(3):209\u2013215.", "@id": "108", "ref-info": {"ref-publicationyear": {"@first": "1993"}, "ref-title": {"ref-titletext": "Albumin levels in pregnancy: a hypothesis\u2013decreased levels of albumin are related to increased levels of alpha-fetoprotein"}, "refd-itemidlist": {"itemid": {"$": "0027433577", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "34", "@issue": "3"}, "pagerange": {"@first": "209", "@last": "215"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.E.", "@_fa": "true", "ce:surname": "Maher", "ce:indexed-name": "Maher J.E."}, {"@seq": "2", "ce:initials": "R.L.", "@_fa": "true", "ce:surname": "Goldenberg", "ce:indexed-name": "Goldenberg R.L."}, {"@seq": "3", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Tamura", "ce:indexed-name": "Tamura T."}]}, "ref-sourcetitle": "Early Hum Dev"}}, {"ref-fulltext": "Matsui DM. Therapeutic drug monitoring in pregnancy. Ther Drug Monit. 2012;34(5):507\u2013511.", "@id": "109", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Therapeutic drug monitoring in pregnancy"}, "refd-itemidlist": {"itemid": {"$": "84866564629", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "34", "@issue": "5"}, "pagerange": {"@first": "507", "@last": "511"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.M.", "@_fa": "true", "ce:surname": "Matsui", "ce:indexed-name": "Matsui D.M."}]}, "ref-sourcetitle": "Ther Drug Monit"}}, {"ref-fulltext": "Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. Aids. 2006;20(15):1931\u20131939.", "@id": "110", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Reduced lopinavir exposure during pregnancy"}, "refd-itemidlist": {"itemid": {"$": "33748911183", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "20", "@issue": "15"}, "pagerange": {"@first": "1931", "@last": "1939"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.M.", "@_fa": "true", "ce:surname": "Stek", "ce:indexed-name": "Stek A.M."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Mirochnick", "ce:indexed-name": "Mirochnick M."}, {"@seq": "3", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Capparelli", "ce:indexed-name": "Capparelli E."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Fayet-Mello A, Buclin T, Guignard N, et al. Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum:implications for dosage adjustments in pregnant women. Antivir Ther. 2013;18(2):171\u2013182.", "@id": "111", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women"}, "refd-itemidlist": {"itemid": {"$": "84875643039", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "18", "@issue": "2"}, "pagerange": {"@first": "171", "@last": "182"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Fayet-Mello", "ce:indexed-name": "Fayet-Mello A."}, {"@seq": "2", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Buclin", "ce:indexed-name": "Buclin T."}, {"@seq": "3", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Guignard", "ce:indexed-name": "Guignard N."}]}, "ref-sourcetitle": "Antivir Ther"}}, {"ref-fulltext": "Santini-Oliveira M, Estrela RDE, Veloso VG, et al. Randomized clinical trial comparing the pharmacokinetics of standard- and increased- dosage lopinavir- ritonavir coformulation tablets In HIV-positive pregnant women. Antimicrob Agents Chemother. 2014;58(5):2884\u20132893.\u2022 This study demonstrated that standard dose of lopinavir/ritonavir is sufficient for pregnancy infected with wild-type virus, but an increased dose may be necessary for resistance mutations.", "@id": "112", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Randomized clinical trial comparing the pharmacokinetics of standard- and increased- dosage lopinavir- ritonavir coformulation tablets In HIV-positive pregnant women"}, "refd-itemidlist": {"itemid": {"$": "84898658017", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "58", "@issue": "5"}, "pagerange": {"@first": "2884", "@last": "2893"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Santini-Oliveira", "ce:indexed-name": "Santini-Oliveira M."}, {"@seq": "2", "ce:initials": "R.D.E.", "@_fa": "true", "ce:surname": "Estrela", "ce:indexed-name": "Estrela R.D.E."}, {"@seq": "3", "ce:initials": "V.G.", "@_fa": "true", "ce:surname": "Veloso", "ce:indexed-name": "Veloso V.G."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Salem AH, Jones AK, Santini-Oliveira M, et al. No need for lopinavir dose adjustment during pregnancy:a population pharmacokinetic and exposure-response analysis in pregnant and nonpregnant HIV-infected subjects. Antimicrob Agents Chemother. 2016;60(1):400\u2013408.", "@id": "113", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "No need for lopinavir dose adjustment during pregnancy: a population pharmacokinetic and exposure-response analysis in pregnant and nonpregnant HIV-infected subjects"}, "refd-itemidlist": {"itemid": {"$": "84957865983", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "60", "@issue": "1"}, "pagerange": {"@first": "400", "@last": "408"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.H.", "@_fa": "true", "ce:surname": "Salem", "ce:indexed-name": "Salem A.H."}, {"@seq": "2", "ce:initials": "A.K.", "@_fa": "true", "ce:surname": "Jones", "ce:indexed-name": "Jones A.K."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Santini-Oliveira", "ce:indexed-name": "Santini-Oliveira M."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, et al. Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. Ther Drug Monit. 2007;29(2):171\u2013176.", "@id": "114", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy"}, "refd-itemidlist": {"itemid": {"$": "34248148055", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "29", "@issue": "2"}, "pagerange": {"@first": "171", "@last": "176"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.F.", "@_fa": "true", "ce:surname": "Lopez-Cortes", "ce:indexed-name": "Lopez-Cortes L.F."}, {"@seq": "2", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Ruiz-Valderas", "ce:indexed-name": "Ruiz-Valderas R."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Rivero", "ce:indexed-name": "Rivero A."}]}, "ref-sourcetitle": "Ther Drug Monit"}}, {"ref-fulltext": "Villani P, Floridia M, Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol. 2006;62(3):309\u2013315.", "@id": "115", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women"}, "refd-itemidlist": {"itemid": {"$": "33747055122", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "62", "@issue": "3"}, "pagerange": {"@first": "309", "@last": "315"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Villani", "ce:indexed-name": "Villani P."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Floridia", "ce:indexed-name": "Floridia M."}, {"@seq": "3", "ce:initials": "M.F.", "@_fa": "true", "ce:surname": "Pirillo", "ce:indexed-name": "Pirillo M.F."}]}, "ref-sourcetitle": "Br J Clin Pharmacol"}}, {"ref-fulltext": "Unadkat JD, Wara DW, Hughes MD, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2007;51(2):783\u2013786.", "@id": "116", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women"}, "refd-itemidlist": {"itemid": {"$": "33846629858", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "51", "@issue": "2"}, "pagerange": {"@first": "783", "@last": "786"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.D.", "@_fa": "true", "ce:surname": "Unadkat", "ce:indexed-name": "Unadkat J.D."}, {"@seq": "2", "ce:initials": "D.W.", "@_fa": "true", "ce:surname": "Wara", "ce:indexed-name": "Wara D.W."}, {"@seq": "3", "ce:initials": "M.D.", "@_fa": "true", "ce:surname": "Hughes", "ce:indexed-name": "Hughes M.D."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Mirochnick M, Best BM, Stek AM, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr. 2011;56(5):412\u2013419.", "@id": "117", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Atazanavir pharmacokinetics with and without tenofovir during pregnancy"}, "refd-itemidlist": {"itemid": {"$": "79953052608", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "56", "@issue": "5"}, "pagerange": {"@first": "412", "@last": "419"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Mirochnick", "ce:indexed-name": "Mirochnick M."}, {"@seq": "2", "ce:initials": "B.M.", "@_fa": "true", "ce:surname": "Best", "ce:indexed-name": "Best B.M."}, {"@seq": "3", "ce:initials": "A.M.", "@_fa": "true", "ce:surname": "Stek", "ce:indexed-name": "Stek A.M."}]}, "ref-sourcetitle": "J Acquir Immune Defic Syndr"}}, {"ref-fulltext": "Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, et al. Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. J Acquir Immune Defic Syndr. 2010;55(3):345\u2013350.", "@id": "118", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women"}, "refd-itemidlist": {"itemid": {"$": "78049272719", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "55", "@issue": "3"}, "pagerange": {"@first": "345", "@last": "350"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Lamorde", "ce:indexed-name": "Lamorde M."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Byakika-Kibwika", "ce:indexed-name": "Byakika-Kibwika P."}, {"@seq": "3", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Okaba-Kayom", "ce:indexed-name": "Okaba-Kayom V."}]}, "ref-sourcetitle": "J Acquir Immune Defic Syndr"}}, {"ref-fulltext": "Olagunju A, Bolaji O, Neary M, et al. Pregnancy affects nevirapine pharmacokinetics:evidence from a CYP2B6 genotype-guided observational study. Pharmacogenet Genomics. 2016;26(8):381\u2013389.", "@id": "119", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study"}, "refd-itemidlist": {"itemid": {"$": "84969663924", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "26", "@issue": "8"}, "pagerange": {"@first": "381", "@last": "389"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Olagunju", "ce:indexed-name": "Olagunju A."}, {"@seq": "2", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Bolaji", "ce:indexed-name": "Bolaji O."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Neary", "ce:indexed-name": "Neary M."}]}, "ref-sourcetitle": "Pharmacogenet Genomics"}}, {"ref-fulltext": "Benaboud S, Ekouevi DK, Urien S, et al. Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. Antimicrob Agents Chemother. 2011;55(1):331\u2013337.", "@id": "120", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates"}, "refd-itemidlist": {"itemid": {"$": "78650633650", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "55", "@issue": "1"}, "pagerange": {"@first": "331", "@last": "337"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Benaboud", "ce:indexed-name": "Benaboud S."}, {"@seq": "2", "ce:initials": "D.K.", "@_fa": "true", "ce:surname": "Ekouevi", "ce:indexed-name": "Ekouevi D.K."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Urien", "ce:indexed-name": "Urien S."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Izurieta P, Kakuda TN, Feys C, et al. Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med. 2011;12(4):257\u2013258.", "@id": "121", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women"}, "refd-itemidlist": {"itemid": {"$": "79952288406", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "12", "@issue": "4"}, "pagerange": {"@first": "257", "@last": "258"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Izurieta", "ce:indexed-name": "Izurieta P."}, {"@seq": "2", "ce:initials": "T.N.", "@_fa": "true", "ce:surname": "Kakuda", "ce:indexed-name": "Kakuda T.N."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Feys", "ce:indexed-name": "Feys C."}]}, "ref-sourcetitle": "HIV Med"}}, {"ref-fulltext": "Tran AH, Best BM, Stek A, et al. Pharmacokinetics of rilpivirine in HIV-infected pregnant women. J Acquir Immune Defic Syndr. 2016;72:289\u2013296; Epub ahead of print.", "@id": "122", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Pharmacokinetics of rilpivirine in HIV-infected pregnant women"}, "refd-itemidlist": {"itemid": {"$": "84959196606", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "72"}, "pagerange": {"@first": "289", "@last": "296"}}, "ref-text": "Epub ahead of print", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.H.", "@_fa": "true", "ce:surname": "Tran", "ce:indexed-name": "Tran A.H."}, {"@seq": "2", "ce:initials": "B.M.", "@_fa": "true", "ce:surname": "Best", "ce:indexed-name": "Best B.M."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Stek", "ce:indexed-name": "Stek A."}]}, "ref-sourcetitle": "J Acquir Immune Defic Syndr"}}, {"ref-fulltext": "Best BM, Burchett S, Li H, et al. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015;16(8):502\u2013511.", "@id": "123", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Pharmacokinetics of tenofovir during pregnancy and postpartum"}, "refd-itemidlist": {"itemid": {"$": "84938744228", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "16", "@issue": "8"}, "pagerange": {"@first": "502", "@last": "511"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.M.", "@_fa": "true", "ce:surname": "Best", "ce:indexed-name": "Best B.M."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Burchett", "ce:indexed-name": "Burchett S."}, {"@seq": "3", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Li", "ce:indexed-name": "Li H."}]}, "ref-sourcetitle": "HIV Med"}}, {"ref-fulltext": "Colbers AP, Hawkins DA, Gingelmaier A, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. Aids. 2013;27(5):739\u2013748.", "@id": "124", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women"}, "refd-itemidlist": {"itemid": {"$": "84876406715", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "27", "@issue": "5"}, "pagerange": {"@first": "739", "@last": "748"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.P.", "@_fa": "true", "ce:surname": "Colbers", "ce:indexed-name": "Colbers A.P."}, {"@seq": "2", "ce:initials": "D.A.", "@_fa": "true", "ce:surname": "Hawkins", "ce:indexed-name": "Hawkins D.A."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Gingelmaier", "ce:indexed-name": "Gingelmaier A."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67\u201376.", "@id": "125", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Pharmacokinetics and drug metabolism in the elderly"}, "refd-itemidlist": {"itemid": {"$": "70149103802", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "41", "@issue": "2"}, "pagerange": {"@first": "67", "@last": "76"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "U.", "@_fa": "true", "ce:surname": "Klotz", "ce:indexed-name": "Klotz U."}]}, "ref-sourcetitle": "Drug Metab Rev"}}, {"ref-fulltext": "Rhee MS, Greenblatt DJ. Pharmacologic consideration for the use of antiretroviral agents in the elderly. J Clin Pharmacol. 2008;48(10):1212\u20131225.", "@id": "126", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Pharmacologic consideration for the use of antiretroviral agents in the elderly"}, "refd-itemidlist": {"itemid": {"$": "51849091134", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "48", "@issue": "10"}, "pagerange": {"@first": "1212", "@last": "1225"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.S.", "@_fa": "true", "ce:surname": "Rhee", "ce:indexed-name": "Rhee M.S."}, {"@seq": "2", "ce:initials": "D.J.", "@_fa": "true", "ce:surname": "Greenblatt", "ce:indexed-name": "Greenblatt D.J."}]}, "ref-sourcetitle": "J Clin Pharmacol"}}, {"ref-fulltext": "Greenblatt DJ. Reduced serum albumin concentration in the elderly:a report from the Boston Collaborative Drug Surveillance Program. J Am Geriatr Soc. 1979;27(1):20\u201322.", "@id": "127", "ref-info": {"ref-publicationyear": {"@first": "1979"}, "ref-title": {"ref-titletext": "Reduced serum albumin concentration in the elderly: a report from the Boston Collaborative Drug Surveillance Program"}, "refd-itemidlist": {"itemid": {"$": "0018415172", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "27", "@issue": "1"}, "pagerange": {"@first": "20", "@last": "22"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.J.", "@_fa": "true", "ce:surname": "Greenblatt", "ce:indexed-name": "Greenblatt D.J."}]}, "ref-sourcetitle": "J Am Geriatr Soc"}}, {"ref-fulltext": "Abernethy DR, Kerzner L. Age effects on alpha-1-acid glycoprotein concentration and imipramine plasma protein binding. J Am Geriatr Soc. 1984;32(10):705\u2013708.", "@id": "128", "ref-info": {"ref-publicationyear": {"@first": "1984"}, "ref-title": {"ref-titletext": "Age effects on alpha-1-acid glycoprotein concentration and imipramine plasma protein binding"}, "refd-itemidlist": {"itemid": {"$": "0021130224", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "32", "@issue": "10"}, "pagerange": {"@first": "705", "@last": "708"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.R.", "@_fa": "true", "ce:surname": "Abernethy", "ce:indexed-name": "Abernethy D.R."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Kerzner", "ce:indexed-name": "Kerzner L."}]}, "ref-sourcetitle": "J Am Geriatr Soc"}}, {"ref-fulltext": "Hilmer SN, Shenfield GM, Le Couteur DG. Clinical implications of changes in hepatic drug metabolism in older people. Ther Clin Risk Manag. 2005;1(2):151\u2013156.", "@id": "129", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Clinical implications of changes in hepatic drug metabolism in older people"}, "refd-itemidlist": {"itemid": {"$": "59149085120", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "1", "@issue": "2"}, "pagerange": {"@first": "151", "@last": "156"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.N.", "@_fa": "true", "ce:surname": "Hilmer", "ce:indexed-name": "Hilmer S.N."}, {"@seq": "2", "ce:initials": "G.M.", "@_fa": "true", "ce:surname": "Shenfield", "ce:indexed-name": "Shenfield G.M."}, {"@seq": "3", "ce:initials": "D.G.", "@_fa": "true", "ce:surname": "Le Couteur", "ce:indexed-name": "Le Couteur D.G."}]}, "ref-sourcetitle": "Ther Clin Risk Manag"}}, {"ref-fulltext": "Kinirons MT, O\u2019Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol. 2004;57(5):540\u2013544.", "@id": "130", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Drug metabolism and ageing"}, "refd-itemidlist": {"itemid": {"$": "2342460306", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "57", "@issue": "5"}, "pagerange": {"@first": "540", "@last": "544"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.T.", "@_fa": "true", "ce:surname": "Kinirons", "ce:indexed-name": "Kinirons M.T."}, {"@seq": "2", "ce:initials": "M.S.", "@_fa": "true", "ce:surname": "O\u2019Mahony", "ce:indexed-name": "O'Mahony M.S."}]}, "ref-sourcetitle": "Br J Clin Pharmacol"}}, {"ref-fulltext": "Winston A, Jose S, Gibbons S, et al. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother. 2013;68(6):1354\u20131359.", "@id": "131", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring"}, "refd-itemidlist": {"itemid": {"$": "84883244574", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "68", "@issue": "6"}, "pagerange": {"@first": "1354", "@last": "1359"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Winston", "ce:indexed-name": "Winston A."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Jose", "ce:indexed-name": "Jose S."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Gibbons", "ce:indexed-name": "Gibbons S."}]}, "ref-sourcetitle": "J Antimicrob Chemother"}}, {"ref-fulltext": "Vanhove GF, Kastrissios H, Gries JM, et al. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997;41(11):2428\u20132432.", "@id": "132", "ref-info": {"ref-publicationyear": {"@first": "1997"}, "ref-title": {"ref-titletext": "Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy"}, "refd-itemidlist": {"itemid": {"$": "0030711596", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "41", "@issue": "11"}, "pagerange": {"@first": "2428", "@last": "2432"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.F.", "@_fa": "true", "ce:surname": "Vanhove", "ce:indexed-name": "Vanhove G.F."}, {"@seq": "2", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Kastrissios", "ce:indexed-name": "Kastrissios H."}, {"@seq": "3", "ce:initials": "J.M.", "@_fa": "true", "ce:surname": "Gries", "ce:indexed-name": "Gries J.M."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Avihingsanon A, Kerr SJ, Punyawudho B, et al. Short communication:aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients. AIDS Res Hum Retroviruses. 2013;29(12):1541\u20131546.", "@id": "133", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Short communication: aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients"}, "refd-itemidlist": {"itemid": {"$": "84888333729", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "29", "@issue": "12"}, "pagerange": {"@first": "1541", "@last": "1546"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Avihingsanon", "ce:indexed-name": "Avihingsanon A."}, {"@seq": "2", "ce:initials": "S.J.", "@_fa": "true", "ce:surname": "Kerr", "ce:indexed-name": "Kerr S.J."}, {"@seq": "3", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Punyawudho", "ce:indexed-name": "Punyawudho B."}]}, "ref-sourcetitle": "AIDS Res Hum Retroviruses"}}, {"ref-fulltext": "Hicks C, Gulick RM. Raltegravir:the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009;48(7):931\u2013939.", "@id": "134", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Raltegravir: the first HIV type 1 integrase inhibitor"}, "refd-itemidlist": {"itemid": {"$": "63649087422", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "48", "@issue": "7"}, "pagerange": {"@first": "931", "@last": "939"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Hicks", "ce:indexed-name": "Hicks C."}, {"@seq": "2", "ce:initials": "R.M.", "@_fa": "true", "ce:surname": "Gulick", "ce:indexed-name": "Gulick R.M."}]}, "ref-sourcetitle": "Clin Infect Dis"}}, {"ref-fulltext": "Baxi SM, Greenblatt RM, Bacchetti P, et al. Common clinical conditions\u2013age, low BMI, ritonavir use, mild renal impairment\u2013affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. Aids. 2014;28(1):59\u201366.", "@id": "135", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Common clinical conditions\u2013age, low BMI, ritonavir use, mild renal impairment\u2013affect tenofovir pharmacokinetics in a large cohort of HIV-infected women"}, "refd-itemidlist": {"itemid": {"$": "84892371096", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "28", "@issue": "1"}, "pagerange": {"@first": "59", "@last": "66"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.M.", "@_fa": "true", "ce:surname": "Baxi", "ce:indexed-name": "Baxi S.M."}, {"@seq": "2", "ce:initials": "R.M.", "@_fa": "true", "ce:surname": "Greenblatt", "ce:indexed-name": "Greenblatt R.M."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Bacchetti", "ce:indexed-name": "Bacchetti P."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Burger D, Teulen M, Eerland J, et al. The international interlaboratory quality control program for measurement of antiretroviral drugs in plasma:a global proficiency testing program. Ther Drug Monit. 2011;33(2):239\u2013243.", "@id": "136", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "The international interlaboratory quality control program for measurement of antiretroviral drugs in plasma: a global proficiency testing program"}, "refd-itemidlist": {"itemid": {"$": "79953216672", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "33", "@issue": "2"}, "pagerange": {"@first": "239", "@last": "243"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Burger", "ce:indexed-name": "Burger D."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Teulen", "ce:indexed-name": "Teulen M."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Eerland", "ce:indexed-name": "Eerland J."}]}, "ref-sourcetitle": "Ther Drug Monit"}}, {"ref-fulltext": "Koehn J, Ho RJ. Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs lopinavir, ritonavir, and tenofovir in plasma. Antimicrob Agents Chemother. 2014;58(5):2675\u20132680.", "@id": "137", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs lopinavir, ritonavir, and tenofovir in plasma"}, "refd-itemidlist": {"itemid": {"$": "84898609027", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "58", "@issue": "5"}, "pagerange": {"@first": "2675", "@last": "2680"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Koehn", "ce:indexed-name": "Koehn J."}, {"@seq": "2", "ce:initials": "R.J.", "@_fa": "true", "ce:surname": "Ho", "ce:indexed-name": "Ho R.J."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit. 2003;25(3):393\u2013399.", "@id": "138", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography"}, "refd-itemidlist": {"itemid": {"$": "0038103469", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "25", "@issue": "3"}, "pagerange": {"@first": "393", "@last": "399"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.A.", "@_fa": "true", "ce:surname": "Droste", "ce:indexed-name": "Droste J.A."}, {"@seq": "2", "ce:initials": "C.P.", "@_fa": "true", "ce:surname": "Verweij-Van Wissen", "ce:indexed-name": "Verweij-Van Wissen C.P."}, {"@seq": "3", "ce:initials": "D.M.", "@_fa": "true", "ce:surname": "Burger", "ce:indexed-name": "Burger D.M."}]}, "ref-sourcetitle": "Ther Drug Monit"}}, {"ref-fulltext": "Jung BH, Rezk NL, Bridges AS, et al. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2007;21(10):1095\u20131104.", "@id": "139", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry"}, "refd-itemidlist": {"itemid": {"$": "34548287060", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "21", "@issue": "10"}, "pagerange": {"@first": "1095", "@last": "1104"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.H.", "@_fa": "true", "ce:surname": "Jung", "ce:indexed-name": "Jung B.H."}, {"@seq": "2", "ce:initials": "N.L.", "@_fa": "true", "ce:surname": "Rezk", "ce:indexed-name": "Rezk N.L."}, {"@seq": "3", "ce:initials": "A.S.", "@_fa": "true", "ce:surname": "Bridges", "ce:indexed-name": "Bridges A.S."}]}, "ref-sourcetitle": "Biomed Chromatogr"}}, {"ref-fulltext": "Gandhi M, Ameli N, Bacchetti P, et al. Protease inhibitor levels in hair strongly predict virologic response to treatment. Aids. 2009;23(4):471\u2013478.", "@id": "140", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Protease inhibitor levels in hair strongly predict virologic response to treatment"}, "refd-itemidlist": {"itemid": {"$": "62349118443", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "23", "@issue": "4"}, "pagerange": {"@first": "471", "@last": "478"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Gandhi", "ce:indexed-name": "Gandhi M."}, {"@seq": "2", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Ameli", "ce:indexed-name": "Ameli N."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Bacchetti", "ce:indexed-name": "Bacchetti P."}]}, "ref-sourcetitle": "Aids"}}, {"ref-fulltext": "Brambilla D, Jennings C, Aldrovandi G, et al. Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA:measurement, precision, and RNA stability. J Clin Microbiol. 2003;41(5):1888\u20131893.", "@id": "141", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability"}, "refd-itemidlist": {"itemid": {"$": "0037614916", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "41", "@issue": "5"}, "pagerange": {"@first": "1888", "@last": "1893"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Brambilla", "ce:indexed-name": "Brambilla D."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Jennings", "ce:indexed-name": "Jennings C."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Aldrovandi", "ce:indexed-name": "Aldrovandi G."}]}, "ref-sourcetitle": "J Clin Microbiol"}}, {"ref-fulltext": "Rakhmanina NY, Capparelli EV, Van Den Anker JN, et al. Nevirapine concentration in nonstimulated saliva:an alternative to plasma sampling in children with human immunodeficiency virus infection. Ther Drug Monit. 2007;29(1):110\u2013117.", "@id": "142", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection"}, "refd-itemidlist": {"itemid": {"$": "33847121755", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "29", "@issue": "1"}, "pagerange": {"@first": "110", "@last": "117"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "N.Y.", "@_fa": "true", "ce:surname": "Rakhmanina", "ce:indexed-name": "Rakhmanina N.Y."}, {"@seq": "2", "ce:initials": "E.V.", "@_fa": "true", "ce:surname": "Capparelli", "ce:indexed-name": "Capparelli E.V."}, {"@seq": "3", "ce:initials": "J.N.", "@_fa": "true", "ce:surname": "Van Den Anker", "ce:indexed-name": "Van Den Anker J.N."}]}, "ref-sourcetitle": "Ther Drug Monit"}}, {"ref-fulltext": "Gras A, Schneider S, Karasi JC, et al. Evaluation of saliva as an alternative matrix for monitoring plasma zidovudine, lamivudine and nevirapine concentrations in Rwanda. Curr HIV Res. 2011;9(4):223\u2013228.", "@id": "143", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Evaluation of saliva as an alternative matrix for monitoring plasma zidovudine, lamivudine and nevirapine concentrations in Rwanda"}, "refd-itemidlist": {"itemid": {"$": "79959961562", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "9", "@issue": "4"}, "pagerange": {"@first": "223", "@last": "228"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Gras", "ce:indexed-name": "Gras A."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Schneider", "ce:indexed-name": "Schneider S."}, {"@seq": "3", "ce:initials": "J.C.", "@_fa": "true", "ce:surname": "Karasi", "ce:indexed-name": "Karasi J.C."}]}, "ref-sourcetitle": "Curr HIV Res"}}, {"ref-fulltext": "Parienti -J-J, Barrail-Tran A, Duval X, et al. Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob Agents Chemother. 2013;57(5):2265\u20132271.", "@id": "144", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial"}, "refd-itemidlist": {"itemid": {"$": "84876232431", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "57", "@issue": "5"}, "pagerange": {"@first": "2265", "@last": "2271"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.-J.", "@_fa": "true", "ce:surname": "Parienti", "ce:indexed-name": "Parienti J.-J."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Barrail-Tran", "ce:indexed-name": "Barrail-Tran A."}, {"@seq": "3", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Duval", "ce:indexed-name": "Duval X."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses. 2003;19(9):825\u2013835.", "@id": "145", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Protein binding in antiretroviral therapies"}, "refd-itemidlist": {"itemid": {"$": "0141481966", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "19", "@issue": "9"}, "pagerange": {"@first": "825", "@last": "835"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Boffito", "ce:indexed-name": "Boffito M."}, {"@seq": "2", "ce:initials": "D.J.", "@_fa": "true", "ce:surname": "Back", "ce:indexed-name": "Back D.J."}, {"@seq": "3", "ce:initials": "T.F.", "@_fa": "true", "ce:surname": "Blaschke", "ce:indexed-name": "Blaschke T.F."}]}, "ref-sourcetitle": "AIDS Res Hum Retroviruses"}}, {"ref-fulltext": "Prasitsuebsai W, Kerr SJ, Truong KH, et al. Using lopinavir concentrations in hair samples to assess treatment outcomes on second-line regimens among Asian children. AIDS Res Hum Retroviruses. 2015;31(10):1009\u20131014.", "@id": "146", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Using lopinavir concentrations in hair samples to assess treatment outcomes on second-line regimens among Asian children"}, "refd-itemidlist": {"itemid": {"$": "84941950858", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "31", "@issue": "10"}, "pagerange": {"@first": "1009", "@last": "1014"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Prasitsuebsai", "ce:indexed-name": "Prasitsuebsai W."}, {"@seq": "2", "ce:initials": "S.J.", "@_fa": "true", "ce:surname": "Kerr", "ce:indexed-name": "Kerr S.J."}, {"@seq": "3", "ce:initials": "K.H.", "@_fa": "true", "ce:surname": "Truong", "ce:indexed-name": "Truong K.H."}]}, "ref-sourcetitle": "AIDS Res Hum Retroviruses"}}, {"ref-fulltext": "Gandhi M, Greenblatt RM. Hair it is:the long and short of monitoring antiretroviral treatment. Ann Intern Med. 2002;137(8):696\u2013697.", "@id": "147", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "Hair it is: the long and short of monitoring antiretroviral treatment"}, "refd-itemidlist": {"itemid": {"$": "0037108644", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "137", "@issue": "8"}, "pagerange": {"@first": "696", "@last": "697"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Gandhi", "ce:indexed-name": "Gandhi M."}, {"@seq": "2", "ce:initials": "R.M.", "@_fa": "true", "ce:surname": "Greenblatt", "ce:indexed-name": "Greenblatt R.M."}]}, "ref-sourcetitle": "Ann Intern Med"}}, {"ref-fulltext": "Gandhi M, Ameli N, Bacchetti P, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011;52(10):1267\u20131275.\u2022 This study showed that atazanavir hair concentrations were the strongest predictor of virological outcomes.", "@id": "148", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy"}, "refd-itemidlist": {"itemid": {"$": "79955450039", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "52", "@issue": "10"}, "pagerange": {"@first": "1267", "@last": "1275"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Gandhi", "ce:indexed-name": "Gandhi M."}, {"@seq": "2", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Ameli", "ce:indexed-name": "Ameli N."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Bacchetti", "ce:indexed-name": "Bacchetti P."}]}, "ref-sourcetitle": "Clin Infect Dis"}}, {"ref-fulltext": "Hugen PW, Langebeek N, Burger DM, et al. Assessment of adherence to HIV protease inhibitors:comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr. 2002;30(3):324\u2013334.", "@id": "149", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring"}, "refd-itemidlist": {"itemid": {"$": "0036639969", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "30", "@issue": "3"}, "pagerange": {"@first": "324", "@last": "334"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.W.", "@_fa": "true", "ce:surname": "Hugen", "ce:indexed-name": "Hugen P.W."}, {"@seq": "2", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Langebeek", "ce:indexed-name": "Langebeek N."}, {"@seq": "3", "ce:initials": "D.M.", "@_fa": "true", "ce:surname": "Burger", "ce:indexed-name": "Burger D.M."}]}, "ref-sourcetitle": "J Acquir Immune Defic Syndr"}}, {"ref-fulltext": "Mitty JA, Stone VE, Sands M, et al. Directly observed therapy for the treatment of people with human immunodeficiency virus infection:a work in progress. Clin Infect Dis. 2002;34(7):984\u2013990.", "@id": "150", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress"}, "refd-itemidlist": {"itemid": {"$": "0036531891", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "34", "@issue": "7"}, "pagerange": {"@first": "984", "@last": "990"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.A.", "@_fa": "true", "ce:surname": "Mitty", "ce:indexed-name": "Mitty J.A."}, {"@seq": "2", "ce:initials": "V.E.", "@_fa": "true", "ce:surname": "Stone", "ce:indexed-name": "Stone V.E."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Sands", "ce:indexed-name": "Sands M."}]}, "ref-sourcetitle": "Clin Infect Dis"}}]}}}}, "affiliation": [{"affiliation-city": "Bangkok", "@id": "60028190", "affilname": "Chulalongkorn University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190", "affiliation-country": "Thailand"}, {"affiliation-city": "Kensington", "@id": "60026655", "affilname": "The Kirby Institute", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026655", "affiliation-country": "Australia"}, {"affiliation-city": "Bangkok", "@id": "60016965", "affilname": "The HIV Netherlands Australia Thailand Research Collaboration", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965", "affiliation-country": "Thailand"}, {"affiliation-city": "Nijmegen", "@id": "60002573", "affilname": "Radboud University Medical Center", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002573", "affiliation-country": "Netherlands"}, {"affiliation-city": "Amsterdam", "@id": "60002483", "affilname": "Universiteit van Amsterdam", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002483", "affiliation-country": "Netherlands"}, {"affiliation-city": "Chiang Mai", "@id": "60000881", "affilname": "Chiang Mai University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881", "affiliation-country": "Thailand"}], "coredata": {"srctype": "j", "eid": "2-s2.0-84996607034", "dc:description": "Introduction: Therapeutic drug monitoring (TDM) may be beneficial when applied to antiretroviral (ARV). Even though TDM can be a valuable strategy in HIV management, its role remains controversial. Areas covered: This review provides a comprehensive update on important issues relating to TDM of ARV drugs in HIV-infected patients. Articles from PubMed with keywords relevant to each topic section were reviewed. Search strategies limited to articles published in English. Expert commentary: There is evidence supporting the use of TDM in HIV treatment. However, some limitations need to be considered. The evidence supporting the use of routine TDM for all patients is limited, as it is not clear that this strategy offers any advantages over TDM for selected indications. Selected groups of patients including patients with physiological changes, patients with drug-drug interactions or toxicity, and the elderly could potentially benefit from TDM, as optimized dosing is challenging in these populations.", "pubmed-id": "27626677", "prism:coverDate": "2016-12-01", "prism:aggregationType": "Journal", "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/84996607034", "dc:creator": {"author": [{"ce:given-name": "Baralee", "preferred-name": {"ce:given-name": "Baralee", "ce:initials": "B.", "ce:surname": "Punyawudho", "ce:indexed-name": "Punyawudho B."}, "@seq": "1", "ce:initials": "B.", "@_fa": "true", "affiliation": {"@id": "60000881", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881"}, "ce:surname": "Punyawudho", "@auid": "23976628300", "author-url": "https://api.elsevier.com/content/author/author_id/23976628300", "ce:indexed-name": "Punyawudho B."}]}, "link": [{"@_fa": "true", "@rel": "self", "@href": "https://api.elsevier.com/content/abstract/scopus_id/84996607034"}, {"@_fa": "true", "@rel": "scopus", "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84996607034&origin=inward"}, {"@_fa": "true", "@rel": "scopus-citedby", "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84996607034&origin=inward"}], "source-id": "10300153301", "citedby-count": "36", "prism:volume": "9", "subtype": "re", "dc:title": "Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients", "openaccess": "0", "prism:issn": "17512441 17512433", "publishercopyright": "\u00a9 2016 Informa UK Limited, trading as Taylor & Francis Group.", "prism:issueIdentifier": "12", "subtypeDescription": "Review", "prism:publicationName": "Expert Review of Clinical Pharmacology", "prism:pageRange": "1583-1595", "prism:endingPage": "1595", "openaccessFlag": "false", "prism:doi": "10.1080/17512433.2016.1235972", "prism:startingPage": "1583", "dc:identifier": "SCOPUS_ID:84996607034", "dc:publisher": "Taylor and Francis Ltdinfo@expert-reviews.com"}, "idxterms": {"mainterm": [{"$": "Anti-HIV Agents", "@weight": "b", "@candidate": "n"}, {"$": "Drug Monitoring", "@weight": "b", "@candidate": "n"}, {"$": "Drug Resistance, Viral", "@weight": "b", "@candidate": "n"}, {"$": "HIV Infections", "@weight": "b", "@candidate": "n"}, {"$": "HIV-1", "@weight": "b", "@candidate": "n"}, {"$": "Humans", "@weight": "b", "@candidate": "n"}]}, "language": {"@xml:lang": "eng"}, "authkeywords": {"author-keyword": [{"@_fa": "true", "$": "antiretroviral drugs"}, {"@_fa": "true", "$": "HIV"}, {"@_fa": "true", "$": "Therapeutic drug monitoring"}]}, "subject-areas": {"subject-area": [{"@_fa": "true", "$": "Pharmacology, Toxicology and Pharmaceutics (all)", "@code": "3000", "@abbrev": "PHAR"}, {"@_fa": "true", "$": "Pharmacology (medical)", "@code": "2736", "@abbrev": "MEDI"}]}, "authors": {"author": [{"ce:given-name": "Baralee", "preferred-name": {"ce:given-name": "Baralee", "ce:initials": "B.", "ce:surname": "Punyawudho", "ce:indexed-name": "Punyawudho B."}, "@seq": "1", "ce:initials": "B.", "@_fa": "true", "affiliation": {"@id": "60000881", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881"}, "ce:surname": "Punyawudho", "@auid": "23976628300", "author-url": "https://api.elsevier.com/content/author/author_id/23976628300", "ce:indexed-name": "Punyawudho B."}, {"ce:given-name": "Noppaket", "preferred-name": {"ce:given-name": "Noppaket", "ce:initials": "N.", "ce:surname": "Singkham", "ce:indexed-name": "Singkham N."}, "@seq": "2", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "60000881", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881"}, "ce:surname": "Singkham", "@auid": "55524284500", "author-url": "https://api.elsevier.com/content/author/author_id/55524284500", "ce:indexed-name": "Singkham N."}, {"ce:given-name": "Narukjaporn", "preferred-name": {"ce:given-name": "Narukjaporn", "ce:initials": "N.", "ce:surname": "Thammajaruk", "ce:indexed-name": "Thammajaruk N."}, "@seq": "3", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "60016965", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965"}, "ce:surname": "Thammajaruk", "@auid": "36451572800", "author-url": "https://api.elsevier.com/content/author/author_id/36451572800", "ce:indexed-name": "Thammajaruk N."}, {"ce:given-name": "Theera", "preferred-name": {"ce:given-name": "Theera", "ce:initials": "T.", "ce:surname": "Dalodom", "ce:indexed-name": "Dalodom T."}, "@seq": "4", "ce:initials": "T.", "@_fa": "true", "affiliation": {"@id": "60016965", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965"}, "ce:surname": "Dalodom", "@auid": "57192085320", "author-url": "https://api.elsevier.com/content/author/author_id/57192085320", "ce:indexed-name": "Dalodom T."}, {"ce:given-name": "Stephen J", "preferred-name": {"ce:given-name": "Stephen J.", "ce:initials": "S.J.", "ce:surname": "Kerr", "ce:indexed-name": "Kerr S.J."}, "@seq": "5", "ce:initials": "S.J.", "@_fa": "true", "affiliation": [{"@id": "60016965", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965"}, {"@id": "60026655", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026655"}, {"@id": "60002483", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002483"}], "ce:surname": "Kerr", "@auid": "7102711578", "author-url": "https://api.elsevier.com/content/author/author_id/7102711578", "ce:indexed-name": "Kerr S.J."}, {"ce:given-name": "David M", "preferred-name": {"ce:given-name": "David M.", "ce:initials": "D.M.", "ce:surname": "Burger", "ce:indexed-name": "Burger D.M."}, "@seq": "6", "ce:initials": "D.M.", "@_fa": "true", "affiliation": {"@id": "60002573", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002573"}, "ce:surname": "Burger", "@auid": "55540576000", "author-url": "https://api.elsevier.com/content/author/author_id/55540576000", "ce:indexed-name": "Burger D.M."}, {"ce:given-name": "Kiat", "preferred-name": {"ce:given-name": "Kiat", "ce:initials": "K.", "ce:surname": "Ruxrungtham", "ce:indexed-name": "Ruxrungtham K."}, "@seq": "7", "ce:initials": "K.", "@_fa": "true", "affiliation": [{"@id": "60016965", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965"}, {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}], "ce:surname": "Ruxrungtham", "@auid": "7004208798", "author-url": "https://api.elsevier.com/content/author/author_id/7004208798", "ce:indexed-name": "Ruxrungtham K."}]}}}